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ABSTRACT 
 
STRUCTURAL DETERMINANTS FOR INHIBITOR RECOGNITION  
BY THE DOPAMINE TRANSPORTER 
 
 
 
By 
Yi Liu 
May 2011 
 
Dissertation supervised by Professor Christopher K. Surratt 
The dissertation will give an introduction, background and our research progress 
in the areas of dopamine transporter (DAT).    A 3-D DAT computer model was 
generated in our laboratory based on the X-ray crystal structure of the bacterial leucine 
transporter LeuT, a distant homolog of DAT.  The ability of this LeuTAa-based 3-D DAT 
computer model to identify specific DAT residues involved in inhibitor recognition was 
assessed through site-directed mutagenesis and subsequent pharmacologic 
characterization in the present study.  Feedback from these experiments confirmed some 
of the suggestion from the DAT model, which is encouraging that the comparative DAT 
model is valid to some extent and could be further used for ligand docking and virtual 
screening.   
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 Non-tropane based photoaffinity labeling compounds were also 
pharmacologically characterized to identify potential probes that could unveil direct 
covalent contacts between the DAT protein and the non-tropane drug. One 
methylphenidate analog was identified among a series of compounds, and was further 
radiolabeled and successfully incorporated into the DAT protein.  Subsequent feedback 
from the crosslinking/proteolysis study could also refine the 3-D DAT model. 
The refined DAT model was used for in silico screening of candidate ligands.  
Ten “hit” compounds were pharmacologically tested.  Three of them displayed moderate 
binding affinities to DAT, supporting the use of combined approaches including 
molecular modeling, mutagenesis and crosslinking/proteolysis for rational drug design of 
novel pharmacotherapeutic ligands to treat psychostimulant addiction and other 
monoamine-related CNS disorders. 
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I.  INTRODUCTION 
 
A. Overview 
Dopamine (DA), a major neurotransmitter in the mammalian central nervous 
system, mediates a wide array of physiological functions including regulation of 
locomotor activity, cognitive processes, neuroendocrine secretion, and the control of 
motivated behaviors.  It is biosynthesized from the amino acid tyrosine and stored in 
synaptic vesicles.  In response to a presynaptic action potential, DA is released into the 
synapse by Ca2+-mediated exocytosis, where it binds to the dopamine receptors on the 
neighboring neuron and activates dopaminergic signal transduction pathways (Fig. 1).  
Dysfunctions in the DA system are believed to contribute to the development of several 
neurological and psychiatric conditions such as Parkinson’s disease, depression, 
schizophrenia, attention deficit hyperactivity disorder (ADHD) and drug addiction 
(Schultz 2002; Arias-Carrion, Stamelou et al. 2010).   
 
The neurotransmission of DA is terminated primarily by reuptake of DA into the 
presynaptic cell via the dopamine transporter (DAT).  Thus, DAT plays a critical role in 
regulating the signal amplitude and duration of dopaminergic neurotransmission by 
mediating the reuptake of the transmitter from the extracellular space back into nerve 
terminals.  DAT belongs to the neurotransmitter: sodium symporter (NSS) family, also 
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referred to as the SLC6 (solute carrier 6) family (Saier 1999), that includes transporters 
for norepinephrine, serotonin, glycine and GABA (Amara and Kuhar 1993).  These 
transporters utilize the transmembrane Na+ gradient as a driving force for transport of 
substrate across the plasma membrane.  They are also characterized by co-transport of Cl-.  
The reuptake process involves a conformational change in the transporter protein 
(Rudnick and Clark 1993).  The mechanism of the translocation process includes at least 
three iconic states: outward-facing (open to outside), occluded, and inward-facing (open 
to inside) (Yamashita, Singh et al. 2005).  The outward-facing transporter recognizes and 
binds Na+, Cl- and substrate.  The binding of substrate and ions triggers the 
conformational change to an inward-facing conformation, allowing the release of the 
substrate and ions to the cytoplasm.   
DAT is expressed almost exclusively in the areas of the brain with established 
dopaminergic circuitry: nigrostriatal, mesolimbic and mesocortical pathways (Ciliax, 
Heilman et al. 1995; Ma, Ciliax et al. 1999).  The mesolimbic and mesocortical pathways 
play key roles in reward assessment.  Dopaminergic projections from the ventral 
tegmental area (VTA) to the limbic areas (nucleus accumbens, ventral striatum and 
amygdala) comprise the mesolimbic pathway, while projections from the VTA to the 
medial, prefrontal, cingulated and entorhinal cortex comprise the mesocortical pathway 
(Marsden 2006).  The nigrostriatal pathway (substantia nigra to the caudate putamen) is 
associated with locomotor activity.  
The DAT is a target of several clinically used drugs, including the 
psychostimulants methylphenidate, D-amphetamine, and modafinil and the 
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antidepressant bupropion. In addition, the reinforcing and euphoric effects of the 
powerfully addictive psychostimulants cocaine and d-methamphetamine (“crystal meth,” 
a vastly more potent analog of amphetamine, often administered in large doses by 
vaporization) are primarily mediated by interaction with the DAT (Mortensen and Amara 
2003; Torres 2006).  Such drugs bind to DAT and inhibit the reuptake of dopamine 
(Kuhar, Ritz et al. 1991).  In addition to inhibiting uptake of extracellular dopamine, 
amphetamines also stimulate efflux of intracellular dopamine (Kahlig, Binda et al. 2005).  
The resultant accumulation of dopamine in the synaptic cleft potentiates 
neurotransmission of dopamine in those areas of the brain associated with reward and 
reinforcement.  Consequently, the motor and reward pathways of the midbrain are 
activated, triggering the increased locomotor activity and euphoria associated with 
psychostimulant drug use.   
Studies using mice lacking DAT demonstrated the importance of the transporter 
in psychostimulant action.  DAT knockout mice display an attenuated response to 
cocaine and amphetamines and a reduced preference for cocaine under self-
administration paradigms (Giros, Jaber et al. 1996).  These mice, however, still self-
administer cocaine, although more sessions were needed to meet self-administration 
criteria (Rocha, Fumagalli et al. 1998).  The finding indicated that developmentally 
compensatory non-dopaminergic mechanisms can mediate cocaine-taking behavior in 
DAT-lacking animals.  In particular, cocaine’s interaction with the serotonin transporter 
(SERT) has been hypothesized to contribute to cocaine reward and reinforcement 
naturally or in compensation for the absence of DAT (Rocha, Fumagalli et al. 1998; 
Mateo, Budygin et al. 2004).  Nevertheless, convincing preclinical evidence implicating 
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specific activity at the DAT in cocaine dependence comes from the observation that the 
reinforcing effect of cocaine is lost in transgenic mice expressing a triple point-mutated 
DAT with preserved substrate translocation but little appreciable affinity for cocaine 
(Chen, Tilley et al. 2006).  It is conceivable that elevated basal dopaminergic tone in 
these mice causes adaptive changes, altering the response to cocaine; however, 
knockdown mutant mice with a ~ 90% reduction in DAT expression but with 
functionally unmodified DATs and elevated basal dopamine still exhibit robust, 
wildtype-like preference for cocaine.  Interaction with the DAT is thus necessary for the 
reinforcing effects of cocaine in animals that carry the DAT (Tilley, Cagniard et al. 2007). 
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Figure 2.  Schematic representation of dopaminergic neurotransmission.   
Dopamine, synthesized in the presynaptic neuron, is stored in the synaptic 
vesicles.  Following the arrival of an action potential, dopamine is released into the 
synaptic cleft by Ca2+-mediated exocytosis.  Dopamine binds to the dopamine receptors 
on the postsynaptic neurons and transmits neuronal signals.  Neurotransmission is 
terminated primarily by reuptake of dopamine into the presynaptic neuron via the DAT.  
Cocaine blocks the dopamine reuptake and increases synaptic dopamine concentrations.  
Amphetamine promotes dopamine efflux as well as competes with dopamine for reuptake. 
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B. Statement of the problem 
Cocaine abuse and addiction continues to be a significant public health problem in 
the world.  In the United States, the number of regular cocaine users has not declined 
significantly since 1992.  The National Survey on Drug Use and Health (NSDUH) 
estimates that in 2009 there were 1.6 million current cocaine users aged 12 or older, 
comprising 0.7 percent of the population, similar to the number and rate in 2008.  Drug 
abuse generally inflicts severe medical, social and judicial costs upon the society.  The 
central problem with cocaine addiction is that the risk for relapse is high even after 
treatment and extended periods of abstinence.  During periods of abstinence, the memory 
of the cocaine experience associated with drug use can trigger tremendous craving and 
relapse to drug use (Anker and Carroll 2010; Saunders and Robinson 2010).  Cocaine 
addiction contributes to several medical, psychiatric and psychosocial problems, even the 
spread of human immunodeficiency virus/acquired immune deficiency syndrome 
(HIV/AIDS) and viral hepatitis (as a consequence of sharing contaminated needles).  
Cocaine use is associated with alertness, increased energy and motor activity, 
enhancement of sensation, and euphoria (Preti 2007).  The abuse liabilities of cocaine 
result from its euphorigenic and reinforcing properties.  The reinforcing effects of 
cocaine and its analogs generally correspond with the ability of the drug to inhibit the 
DAT, and thus to potentiate dopamine neurotransmission.  Blockade of this protein 
increases synaptic levels of the neurotransmitter dopamine in the nucleus accumbens and 
other brain regions critical to euphoria and addiction (Ritz, Lamb et al. 1987).  Cocaine 
also increases synaptic concentrations of serotonin and norepinephrine by blockade of the 
cognate transporters, resulting in stimulant and mood-altering effects (Amara and Kuhar 
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1993; Torres 2006).  Despite extensive research, medications that combat the actions of 
cocaine and other psychostimulants at the level of the DAT protein are currently 
unavailable and desperately needed.  To understand the function and regulation of DAT 
could provide rational design for developing useful compounds in combating 
psychostimulant abuse and addiction.   However, the limited information on the structure 
and function of DAT has hindered research progress. 
Obtaining high-resolution DAT structure-function information is therefore key to 
understanding psychostimulant mechanisms of action, and in subsequent developing 
useful therapeutics against psychostimulant abuse and addiction.  The 2005 publication of 
a crystal structure for a NSS/SLC6 homolog, the bacterial leucine transporter LeuT 
(Yamashita, Singh et al. 2005), provided the first reasonable template for three-
dimensional comparative modeling of NSS proteins.  A LeuTAa-directed DAT model was 
generated using the capabilities of the Molecular Operating Environment (MOE) program 
(Indarte, Madura et al. 2008).  The LeuT crystal suggests that the substrate leucine and 
sodium ions are tethered midway through the lipid bilayer in a pocket created primarily 
by the middle, unwound portions of TM 1 and TM 6.  The unwound regions of TM 1 and 
TM 6 are also postulated to be involved in the interconversion of outward- and inward-
facing transporter conformations (Yamashita, Singh et al. 2005).  The conformational 
changes with respect to substrate access are governed by the opening and closing of 
external and internal “gates”.  The external gate is of special interest, as it may be 
relevant to inhibitor action (Yamashita, Singh et al. 2005).  Recent published LeuT-
tricyclic antidepressant (TCA) co-crystal structures indicate that the position of TCA 
drugs is several Angstroms (Å) above the substrate pocket, sitting on the closed external 
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gate (Singh, Yamashita et al. 2007; Zhou, Zhen et al. 2007).  Docking of cocaine to the 
LeuTAa-based DAT model yielded a binding site coinciding with that of TCA drugs in the 
published LeuT cocrystal structures. 
The hypothesis of this study is that a LeuTAa-based 3-D DAT molecular model 
can be used to reveal the ligand binding sites, and as a tool for in silico screening of 
candidate ligands that may serve as lead compounds in development of novel medications 
to combat addiction, depression, Parkinson’s disease, and other DA system related 
dysfunctions.  The ability of this LeuTAa-based 3-D DAT computer model to identify 
specific DAT residues involved in inhibitor recognition was assessed through site-
directed mutagenesis and subsequent pharmacologic characterization in the present study.  
In addition, non-tropane based photoaffinity labeling compounds were also 
pharmacologically characterized to identify potential probes that could unveil direct 
covalent contacts between the DAT protein and the non-tropane drug.  Feedback from 
site-directed mutant pharmacology and crosslinking/proteolysis studies will refine the 3-
D DAT model as a drug screening tool for new potential ligands, aiding the development 
of non-addictive drugs for treating addiction (Fig. 2).  Therefore, the specific aim 1 of this 
study is to determine the role of amino acid residues predicted by the DAT model to be 
involved in inhibitor recognition.  The specific aim 2 is to pharmacologically characterize 
analogs of non-tropane inhibitors for further development of potential probes to detect the 
specific non-tropane drug-DAT contact.  The specific aim 3 is to pharmacologically 
characterize the novel DAT ligands identified through in silico screening using the DAT 
model. 
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Figure 2.  Big picture of the study.  
The 3-D DAT model was created by Dr. Martin Indarte. 
 
 
 
 
 
 
 
 
 
10 
 
The overall goal of this study is to identify specific DAT residues involved in 
inhibitor recognition, using DAT molecular modeling, site-directed mutagenesis, 
pharmacologic characterization, and DAT ligand covalent crosslinking analysis.  The 
study involved three experimental approaches: 1) DAT residues identified by the DAT 
molecular model as key to inhibitor recognition were mutated and pharmacologically 
characterized to verify the inhibitor binding site predicted by the DAT model.  2) 
Analogs of the non-tropane inhibitors pyrovalerone, bupropion and methylphenidate were 
pharmacologically characterized toward developing potential probes to detect specific 
non-tropane drug-DAT protein contacts.  3) The novel DAT ligands identified through in 
silico screening were pharmacologically characterized to verify the ability of the DAT 
model to discover novel ligands that may carry therapeutic promise. 
These three approaches were detailed as follows: 
1) Site-directed mutagenesis – the specific hypothesis to be tested is that DAT model 
docking algorithms can predict inhibitor binding sites that can be verified via 
mutagenesis and pharmacology. 
From the docking simulations between the DAT model and inhibitor ligands, 
several DAT amino acid residues were selected as site-directed mutagenesis targets.  In 
this case, cocaine and benztropine were docked with the DAT model because they are 
suggested to prefer outward- and inward-facing DAT conformations, respectively 
(Loland, Desai et al. 2008).  Amino acids within 7 Å of the drug were considered for 
mutagenesis.  A residue as far as 7 Å away would not directly contact the ligand, but 
could contribute pocket infrastructure that confers binding selectivity.  Ten amino acids 
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suggested from the docking results were selected as the site-directed mutagenesis targets 
(Fig. 3). 
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Figure 3.  DAT side chains implicated in recognition of cocaine and benztropine. 
Docking of cocaine (Panel A, 3-D representation; Panel B, 2-D representation) or 
benztropine (Panel C, 3-D representation; Panel D, 2-D representation) using the 3-D 
DAT model (created by Dr. Martin Indarte) is shown.  Side chains within 7 Angstroms of 
the ligand are pictured.  
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The side chain of R85 (TM1) appears selectively important for benztropine 
recognition due to hydrophobic interactions between the hydrocarbon portion of the side 
chain and aromatic rings of the inhibitor, H-bonding with the ether moiety of the drug.   
D475 (TM 10) could potentially interact with the protonated N-8 tropane atom of cocaine.  
The model also indicated that R85 seems to form a salt bridge with D475 (TM 10) that 
stabilizes the inhibitor binding site.  Moreover, the DAT R85 – D475 salt bridge appears 
to line the floor of the cocaine/TCA binding pocket.  The presence of a salt bridge was 
tested by creation of double mutants in which the side chains at the bridging positions are 
switched (Sahin-Toth, Dunten et al. 1992; Merickel, Kaback et al. 1997).   In this case, 
the switch mutant would be R85D / D475R.  Restoration of wildtype-like transporter 
function in the switch mutant when each single mutation disrupts function can be taken as 
evidence of the presence of the salt bridge.  Confirmation of the DAT model-predicted 
intratransmembranous salt bridge would verify the TM1-TM10 juxtaposition and provide 
an important advance in understanding DAT structure and function.  Thus, single mutants 
R85D and D475R and the switch mutant R85D /D475R were created. 
K92 (TM 1) appears to hydrophobically interact with the inhibitors through the 
straight chain hydrocarbon.  Additionally, a salt bridge with the TM 6 D312 carboxylate 
may provide DAT infrastructure.  To verify the presence of the ion pair, single mutants 
K92D and D312K and the switch mutant K92D/D312K were created. 
Y88 (TM 1) and F542 (TM 11) appear to form π-π stacking with aromatic rings of 
both cocaine and benztropine aromatic groups in the DAT model.  Y88 can also H-bond 
with the C-2 ester of cocaine.  These two residues were selected to be mutated to alanine.   
14 
 
Alanine substitution could eliminate aromaticity but preserve the α-helical nature of the 
transmembrane domain.      
H476 (TM 10) is unique to the DAT.  This residue appears likely to form H-
bonding or hydrophobic interactions with cocaine, but not benztropine.  Alanine 
replacement removes any significant partial positive charge, H-bonding, side chain length 
and any π electron contributions while preserving the α-helical nature of the 
transmembrane domain.      
G425 (TM 8) is conserved among the monoamine transporters (DAT, SERT and 
NET).  The analogous position in LeuT is occupied by I359, which is important for the 
binding site of LeuT (Yamashita, Singh et al. 2005).   Isoleucine substitution should 
lengthen the side chain and increase the steric hindrance; moreover, it may change the 
binding site to mimic that of LeuT. 
D384 (TM 8) and I468 (TM 10) are shown only in the “gate closed” binding 
conformation for cocaine and benztropine.  D384 was mutated to alanine or asparagine, 
while cysteine and alanine replaced I468.  For D384, alanine substitution could remove 
any significant charge and H-bonding potential, while asparagine replacement eliminates 
the negative charge of aspartic acid but retains the side chain length and H-bonding 
potential.  For I468, alanine substitution would shorten the side chain length and decrease 
the size of the side chain, while cysteine replacement could shorten the side chain length 
and add H-bonding potential.  Moreover, alanine is shown in SERT as analogous to 
isoleucine in DAT and NET.  Cysteine mutation could be further used in 
methanethiosulfonate (MTS) alkylation assays that test accessibility to the residue. 
15 
 
T472 (TM 10) directly contacts cocaine in the “gate closed” poses, and also in the 
“gate open” pose for benztropine in the DAT model.  Alanine replacement shortens the 
side chain and eliminates the potential for H-bonding but preserves the α-helical nature of 
the transmembrane domain.  Lysine substitution will lengthen the side chain and preserve 
the H-bonding potential. Moreover, lysine is found in the analogous position of the SERT; 
therefore, mutants T472A and T472K were generated. 
The engineered plasmids encoding the DAT mutations were transiently 
introduced into N2A neuroblastoma cells via the calcium phosphate-DNA precipitation 
technique (Graham and van der Eb 1973) and tested via radioligand binding and uptake 
assays.   
2) Non-tropane inhibitor analog characterization – the specific hypothesis to be tested is 
that a specific non-tropane drug-DAT protein contact can be detected, toward 
mapping the drug binding site. 
Non-tropane-based photoaffinity ligands for the DAT are relatively unexplored, in 
contrast to tropane-based compound such as cocaine and benztropine.  Therefore, novel 
non-tropane analogs for pyrovalerone, bupropion and methylphenidate were synthesized 
by Dr. Lapinsky’s lab and pharmacologically characterized in the present study.  Those 
displaying high DAT affinity were radiolabeled and crosslinked to the DAT protein via 
photolysis.  Upon photolysis of the [125I]-labeled drug, a reactive nitrene group on the 
drug will form a covalent bond with the nearest appropriate DAT residue.  DAT 
proteolysis and western blotting with one of many epitope position-specific DAT 
antibodies will identify the DAT region corresponding to the radiolabeled fragment (Fig. 
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4).  The DAT model will indicate the most likely residue(s) for the point of crosslink, and 
these targets will be addressed via site-directed mutagenesis. 
 
Figure 4.  Schematic representation of crosslinking analysis.  
Photoaffinity labeling probe will covalently bind to the target protein through 
reactive group (e.g. nitrene) crosslinking.  The complex will then be fragmented.  The 
radiolabeled fragment will be purified and identified through western blot assay. 
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Using stably-transfected N2A cells bearing WT hDAT, all non-tropane analogs 
from the Lapinsky lab were assessed for binding affinity (measured by [3H]-WIN 35,428 
displacement) and [3H]-dopamine uptake inhibition potency (DUIP).  Compounds with 
low nanomolar DAT affinities and potencies were forwarded to the Lever lab for 
radioiodination, and then to the Vaughan lab for crosslinking, proteolysis and analysis.   
N
O O
OO
Cocaine
NO
Benztropine
O
N
Pyrovalerone
Cl
NH
O
Bupropion
NH O
O
CH3
Methylphenidate  
Figure 5.  Chemical structures of tropane-based and non-tropane-based DAT 
inhibitors.  
The tropane moiety is highlighted with the dashed circle in the structures of 
cocaine and benztropine.  
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3) Characterization of virtual screening “hit” compounds – the specific hypothesis to be 
tested is that the DAT model can be used for virtual screening to discover novel 
ligands that may carry therapeutic promise. 
Inhibitor binding pocket, defined by the refined model, was unveiled to be located 
in the vestibule area.  This vestibule pocket was then used for virtual screening of a 
structure library of compounds.  Top ranked virtual screening (VS) “hit” compounds 
(predicted to be high affinity at the DAT) from the in silico screen were purchased and 
tested at the bench via DAT binding/uptake assays using the N2A DAT cell line (Fig. 6).   
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Figure 6.  Schematic illustration of virtual screening approach.  
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C. Literature Survey 
1. Structure of the Dopamine Transporter 
The human DAT, which is located in chromosome 5p15.3 (Giros, Jaber et al. 
1996), encodes 620 amino acids in its primary sequence.  Up to date, no X-ray 
crystallographic or high-resolution structural information is available for the topological 
assignments of DAT, or any other member of the family of mammalian monoamine 
transporters (MATs).  Hydropathy analysis (Kilty, Lorang et al. 1991; Shimada, 
Kitayama et al. 1991) of the primary sequences of MATs predicts a topology with 12 
transmembrane-spanning segments connected by alternating extracellular and 
intracellular loops with the amino and carboxyl termini located in the cytosol (Fig. 7).   
This theoretical arrangement has been at least partially confirmed by experimental 
evidence.  A study using cysteine/lysine-modifying reagents and biotinylated probe 
scanning has demonstrated the proposed topology on predicting extracellular domains of 
the serotonin transporter (Chen and Justice 1998).  The intracellular location of the N-
terminus and the extracellular location of the loop between TM 3 and TM 4 have been 
confirmed by the immunoperoxidase and immunogold electron microscopy, using 
monoclonal antibodies specific for the N-terminus and the second extracellular loop 
(Nirenberg, Vaughan et al. 1996; Hersch, Yi et al. 1997).  By use of proteolysis and 
epitope-specific immunoprecipitation of photolabeled DAT, it demonstrates the presence 
of at least one transmembrane helix or other membrane-anchoring structures in two 
different regions of the protein predicted to contain transmembrane domains and again 
identifies the extracellular orientation of the region between TM 3 and TM 4 (Vaughan 
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and Kuhar 1996).  Experiments with membrane permeable and impermeable Cys-
selective chemical modification reagents confirm the extracellular location of C90 and 
C306, and intracellular locations of C135 and C342 in human DAT (hDAT) (Ferrer and 
Javitch 1998).  In addition, three residues on the extracellular face of the hDAT (H193, 
H375, and E396), have been characterized to form three coordinates in the Zn2+-binding 
site.  The common participation of these amino acids in binding the Zn2+ ion suggests a 
close proximity between extracellular loop 2, TM 7, and TM 8 in the tertiary structure of 
the hDAT (Norregaard, Frederiksen et al. 1998; Loland, Norregaard et al. 1999).   
DAT is a glycoprotein with an apparent molecular mass of ~80 kDa as 
determined by gel electrophoresis.  N-deglycosylation of DAT by glycosidase reduces the 
molecular mass to ~50 kDa (Vaughan and Kuhar 1996; Patel 1997).  Several putative N-
glycosylation sites are found in the second extracellular loop located between TM 3 and 
TM 4.  Mutagenesis studies have demonstrated that the glycosylation is critical for the 
activity and stability of the DAT at the surface (Torres, Carneiro et al. 2003; Li, Chen et 
al. 2004).  The stability and trafficking of the human norepinephrine transporter (hNET) 
to the membrane has been shown largely dependent on glycosylation of the consensus 
sites (Melikian, Ramamoorthy et al. 1996; Nguyen and Amara 1996).   
Two cysteines (C180 and C189) in the second extracellular loop, conserved in 
MATs, are predicted to form a disulfide bond in DAT.  Substitution of these cysteine 
residues dramatically reduced the cell surface expression of rat DAT (rDAT) or SERT 
proteins (Wang, Moriwaki et al. 1995; Chen, Liu-Chen et al. 1997).  Random 
mutagenesis at either or both cysteines impaired the function of mutated drosophila 
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DATs.    Furthermore, a mutated drosophila DAT with all cysteines removed except the 
two cysteines in extracellular loop 2 (ECL2) demonstrated the presence of disulfide 
bridge.  The breaking of the disulfide bond by DTT treatment did not affect transport 
activity (Chen, Wei et al. 2007).  These results suggest that the disulfide bridge between 
these cysteines in ECL2 is essential for DAT biosynthesis and its delivery to the cell 
surface, but not necessary for its uptake function.  
The primary sequence of DAT contains several predicted protein kinase sites in 
the putative intracellular domains (Kilty, Lorang et al. 1991; Shimada, Kitayama et al. 
1991).  Mutagenesis studies have revealed phosphorylation sites for Protein Kinase C 
(PKC), PI-3 kinase and ERK1/2 (Chang, Lee et al. 2001; Lin, Zhang et al. 2003).  A 
cluster of six serines, located at the distal end of the DAT N-terminal via enzymatic 
cleavage, phopho-peptide mapping, amino acid analysis and truncation studies (Foster, 
Pananusorn et al. 2002), are phosphorylated following PKC activation or phosphatase 
inhibition (Foster, Pananusorn et al. 2002; Granas, Ferrer et al. 2003; Cervinski, Foster et 
al. 2005).    Several serines and threonines are also found located at the N-terminal more 
proximal to the membrane, containing consensus motifs for PKC, Protein Kinase A (PKA) 
and proline-directed kinases (Gorentla, Moritz et al. 2009).  Serine and threonine residues 
at DAT C-terminal have been suggested as potential phosphorylation sites for PKC, PKA 
and proline-directed kinases (Chang, Lee et al. 2001; Gorentla, Moritz et al. 2009).  PKC 
mediated DAT phosphorylation has been suggested to cause the sequestration of the 
transporter protein (Zhu, Kavanaugh et al. 1997; Melikian and Buckley 1999) and 
downregulation of transporter activity (Huff, Vaughan et al. 1997; Vaughan, Huff et al. 
1997).  While a recent mutagenesis study found that the elimination of PKC mediated N-
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tail DAT phosphorylation fails to prevent the internalization of the transporter, implying 
that N-terminal phosphorylation is not important for DAT internalization (Chang, Lee et 
al. 2001; Granas, Ferrer et al. 2003).   Threonines on the proximal of N-terminal are 
phosphorylated by proline-directed kinases (e.g. ERK1/2, p38MAPK and JUN).  
Moreover, T53 is indicated as the phosphorylation site of ERK1/2 (Gorentla, Moritz et al. 
2009).  The functional implication of T53 and other amino acids associated with DAT 
phosphorylation has not yet determined.   
 
 
Figure 7.  Schematic illustration of DAT topology.   
The dopamine transporter has 12 transmembrane domains and a large second 
extracellular loop with several putative N-glycosylation sites.  Both N- and C-termini  are 
located on the intracellular side of the membrane with several predicted protein kinase 
sites.   
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2. Mechanism of Substrate Transport 
The reuptake of monoamine is driven by the ion concentration gradient that is 
generated by the plasma membrane Na+/K+ ATPase.  In the case of DAT, two Na+ ions 
and one Cl- ion are transported with the substrate, while SERT and NET co-transport 
their respective substrates with one Na+ ion and one Cl- ion.  SERT additionally transports 
K+ in antiport fashion (Rudnick and Clark 1993; Torres, Gainetdinov et al. 2003).  
Na+/Cl- – dependent transporters, like many ion channels, have selective binding sites for 
substrate and ions.  However, these transporters, unlike most ion channels, are believed to 
possess two “gates” that can alternately allow access to the binding sites from either side 
of the membrane bilayer (Jardetzky 1966; Johnson, Eshleman et al. 1998; Pifl and Singer 
1999).  Binding of dopamine, Na+
 
and Cl- to DAT on the extracellular side induces a 
conformational change in the transporter allowing the exposure of the binding site to the 
intracellular side of the membrane.  Dopamine and the ions are translocated into the cell 
and the empty transporter returns to the outward facing conformation to initiate another 
transport cycle (Reith 1997; Zhang and Rudnick 2006). 
The crystal structure of LeuTAa (NSS/SLC6 homolog) unveils the amino acid 
residues and TMs that compromise the extracellular and intracellular gates, as well as 
conformational changes that the transporter might undergo during the translocation cycle.  
Extracellular gate of LeuTAa, is formed primarily by Y108 (TM 3), F258 (TM 6), R30 
(TM 1) and D404 (TM 10).  In contrast to extracellular gate, intracellular gate is more 
substantial, involving R5 (TM 1), W8 (TM 1), D369 (TM 10), T265 (TM 6), S267 (TM 6) 
and T268 (TM 6).  At least three conformational states are suggested to occur during the 
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transport process: open-to-outside (outward facing), occluded (substrate and ion bound) 
and open-to-inside (inward facing) (Yamashita, Singh et al. 2005).   
Outward facing conformation allows substrate and ions binding.  The binding of 
substrate and ions trigger the conformation transitions to the occluded (substrate- and ion-
bound) state, and subsequent inward facing conformation allowing the release of 
substrate and ions into the cytoplasm (Fig. 8, A, B and C).  Although the substrate and 
ion binding sites are accessible from both sides of the membrane, the access from the 
extracellular side is suggested to be easier than access from the intracellular side, given 
the fact that the ‘thickness’ of protein occluding the substrate/ion binding pockets from 
the extracellular side of the membrane is much smaller than that shielding the binding site 
from the cytoplasmic side.  Moreover, compared to the intracellular gate, less substantial 
extracellular gate or barrier might allow substrates and ions to bind and unbind more 
quickly from the extracellular side in comparison with the cytoplasmic side.  Thus, the 
transporter may tend to preferentially stay in outward facing state, ready for substrates 
and ions binding (Gouaux 2009).   
With respect to inhibition of substrate translocation by inhibitors, distinct steps of 
transport cycle are postulated to be involved (Fig 8, D and E).  In the case of LeuTAa, 
competitive inhibitor displaces the substrate and traps the transporter in an open-to-out 
conformation, thereby preventing progression to the next transport step (occluded state).  
Whereas non-competitive inhibitor binds to the secondary binding pocket and stabilizes 
the transporter in the occluded state, thus preventing the translocation cycle (Singh, 
Piscitelli et al. 2008).  
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Figure 8.  Schematic illustration of transport mechanism and inhibition in LeuT 
(Singh, Piscitelli et al. 2008) 
A mechanism to describe the activity of LeuT that involves binding of substrates 
and ions to an open-to-the outside conformation (A), isomerization to an occluded state 
(B), and subsequent isomerization to an open-to-the-inside conformation (C), and from 
the open-to-in (C) back to the open-to-out state (A).  Effect of the competitive inhibitor 
Trp on transporter: stabilizing the open-to-out conformation (D).  Effect of the 
noncompetitive TCA inhibitors on transport-stabilizing the outward-facing occluded 
conformation (E).  The boxed conformations represent actual crystal structures, whereas 
the unboxed conformations are hypothetical. 
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3. Substrate and Inhibitor Selectivity of the DAT 
3.1 DAT Substrates 
HO
HO
NH2 HO
HO
H
N
R
H
N
CH3O
O
Dopamine Amphetamine
Methamphetamine
R = H
R = CH3
MDMA
 
Figure 9. The structures of DAT substrates. 
Amphetamines 
 The most commonly studied DAT substrates are amphetamines, including 
amphetamine and methamphetamine (Fig. 9).  S-(+)-amphetamine releases dopamine 
with an EC50 of 8.7 nM; the R-(−)-amphetamine is 3-fold weaker, at 27.7 nM (EC50) 
(Blough, Page et al. 2005). Although weaker, a similar trend is seen for the optical 
isomers of methamphetamine. S-(+)-methamphetamine releases dopamine with an EC50 
of 24.5 nM, while the R-(−)-methamphetamine is 16-fold less active at 416 nM (EC50) 
(Blough, Page et al. 2005). 
MDMA 
 MDMA (Fig. 9), a 3,4-methylenelioxy analog of methamphetamine, is much 
weaker than amphetamine as a dopamine releaser. MDMA releases dopamine with an 
EC50 value of 278nM, compared to the more potent compound amphetamine (EC50 = 8.7 
nM) (Rothman and Baumann 2006). 
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3.2 DAT Inhibitors 
3.2.1 Tropane-Based DAT inhibitors 
N
H3C
CO2CH3
O
O
N
H3C
CO2CH3
R
N
H3C
O
Cocaine WIN 35,065 R = H
WIN 35,428 R = F
Benztropine
 
Figure 10. The structures of tropane-based DAT inhibitors. 
WIN Compounds 
 Due to the significant abuse and dependence liability of cocaine, analogs of 
cocaine were synthesized in the early 1970s in the hope of finding a useful stimulant or 
antidepressant. Some of the most potent behavioral stimulants that were discovered at 
this time were later known as WIN 35,065 and WIN 35,428 (Fig. 10) (Clarke 1977). 
These compounds were analogs of cocaine in which the benzoyl ester has been replaced 
by a phenyl group linked directly to the tropane ring. WIN 35,065 and WIN 35,428 were 
16- and 64-times as active as cocaine, respectively, in terms of their potency to increase 
locomotor activity in mice, and WIN 35,428 was described as lasing for more than 5 
hours (Clarke, Daum et al. 1973). [3H]WIN 35,428, a radiolabelled form of WIN 35,428 
has been used in determination of DAT ligand binding affinity. 
Benztropine 
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 Benztropine (Fig. 10) is a drug that has been clinically used for many years as an 
adjunct therapy to reduce motor side effects associated with neuroleptic treatment with 
antipsychotic medications. Benztropine is a molecule with the shared features of a 
tropane ring from cocaine and a diphenyl ether of the phenylpiperazines. There are 
several lines of evidence that suggest that the benztropine bind differently than cocaine to 
the DAT and that those difference in interaction, at the molecular level, may be related 
the actions of benztropine analogs that differ from those of cocaine (Newman and 
Kulkarni 2002).  Early studies employing site-directed mutagenesis of the DAT revealed 
differences in binding modes between cocaine and benztropine (Reith, Berfield et al. 
2001).  In contrast to cocaine, benztropine had no effect on the reaction of Cys-90 with a 
thiosulfonate reagent. In addition, the decrease in the reaction of Cys-135 with a 
thiosulfonate reagent produced by cocaine and other DA-uptake inhibitors was not 
obtained with benztropine (Reith, Berfield et al. 2001). Several other studies have 
demonstrated differences in the actions of benztropine or its analogs with wild-type and 
mutant DAT (Chen, Zhen et al. 2004). Studies using photoaffinity labeling techniques 
have also provided evidence that structurally different dopamine uptake inhibitors 
covalently attach to different TMs in the DAT (Vaughan, Agoston et al. 1999; Zou, 
Kopajtic et al. 2001). 
3.2.2 Non-Tropane-Based DAT inhibitors 
GBR compounds 
 GBR compounds resulted from the replacement of the tropane ring in benztropine 
by a piperazine ring. These compounds represent structurally important class of potent 
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and selective dopamine reuptake inhibitors (Newman and Kulkarni 2002). GBR 12909 
and GBR 12935 (Fig. 11) were among the first agents to characterized as high-affinity 
and selective inhibitors of DAT. Further work identified these compounds as moderately 
selective inhibitors of dopamine uptake over serotonin and norepinephrine uptake (Preti 
2000). Early studies with GBR 12909 noted that it differed from cocaine in several key 
ways (Rothman and Glowa 1995). GBR 12909 has a slower onset of action and longer 
duration of action than that of cocaine (Rothman, Grieg et al. 1992). It possesses a much 
higher affinity for, and slower dissociation rate from, the DAT than cocaine (Rothman, 
Mele et al. 1991). It functionally antagonizes cocaine’s ability to elevate extracellular 
levels of dopamine (Rothman, Mele et al. 1989; Rothman, Mele et al. 1991) and has a 
nonstimulant-like profile in normal human volunteers following oral administration 
(Sogaard, Michalow et al. 1990).    
 
Figure 11. The structures of non-tropane-based DAT inhibitors. 
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Mazindol 
 Mazindol (Fig. 11) is a sympathomimetic amine that is marketed as an 
anorexigenic by several companies and is the major representative of a class of dopamine 
uptake inhibitors.  For a time, it was the tritiated ligand used to measure binding at the 
DAT.  The behavior effects of mazindole were compared with cocaine using squirrel 
monkeys trained to respond under a fixed-interval schedule of stimulus-shock termination.  
Mazindol displayed behavioral effects that were qualitatively similar to those of cocaine, 
producing dose-related increases in response rates  Mazindol was only slightly less potent 
than cocaine in producing this effect (Spealman, Madras et al. 1989).  
Bupropion 
 Bupropion (Fig. 11) is another dopamine-uptake inhibitor that is typically studied 
as standard DAT inhibitor. It is currently marketed as antidepressant and smoking 
cessation aid. Like cocaine, it is a locomotor stimulant. Despite the fully cocaine-like 
profile of bupropion in animal models, it typically does not produce a cocaine-like 
discriminative stimulus effect in human (Rush, Kollins et al. 1998), and it is not generally 
abused. 
Methylphenidate 
 Like mazindol and bupropion, methylphenidate (Fig. 11) is a dopamine-uptake 
inhibitor that has been clinically use for the treatment of attention-deficit hyperactivity 
disorder and narcolepsy for many years, and despite similarities to cocaine, has not been 
widely abused. Methylphenidate has also been used as a standard dopamine-uptake 
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inhibitor in studies determining the contribution of the uptake inhibitor to the behavioral 
effects of cocaine and other ligands.  
4. Structure-Function Analysis of the DAT 
Knowledge of DAT functional group topography is a prerequisite for 
understanding the molecular basis of transporter function, the actions of psychostimulant 
drugs, and mechanisms of dopaminergic neurodegeneration.  Thus, extensive efforts have 
been made to identify the amino acid residues and the domains that participate in 
substrate binding and translocation, and inhibitor binding.   Prior to the publication of 
LeuT crystal structure, approaches such as site-directed mutagenesis, chimeric 
transporters and substituted cysteine accessibility method (SCAM) have been employed 
in structure-function studies. 
Substrate transport- and inhibitor-binding functions have been identified within 
the DAT TM 1-3 and 4-8 regions by using DAT/NET chimeras (Buck and Amara 1994; 
Giros, Wang et al. 1994; Buck and Amara 1995).  Cross-species chimera using bovine 
and human DAT implicated the involvement of TM 3, 6 and 8 in cocaine binding and DA 
transport (Lee, Kang et al. 1998; Lee, Chang et al. 2002).  By use of an irreversible 
affinity labeling approach, binding sites for cocaine, benztropine and GBR classes of 
uptake inhibitors have been investigated.  N-terminal (TM 1and 2) and or/central (TMs 4 
to 7) of DAT has been identified as binding regions (Vaughan and Kuhar 1996; Vaughan, 
Agoston et al. 1999; Vaughan, Gaffaney et al. 2001; Vaughan, Sakrikar et al. 2007).  The 
attachment site of one of the cocaine analogs (RTI-82) has been further localized to TM 6 
(Vaughan, Sakrikar et al. 2007).  Taken together, results of these two approaches 
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correspond well with the contributions of TMs 1, 3, 6 and 8 to the substrate pocket in 
LeuTAa, and also strongly suggest the three-dimensional proximity and contribution of 
TMs 1, 3 and 6 for cocaine binding. 
Site-directed mutagenesis is another approach employed in structure-function 
studies.  To date, over 250 amino acid residues in rDAT and hDAT have been 
investigated and reviewed (Surratt, Ukairo et al. 2005; Volz and Schenk 2005).  Mutation 
of many residues leads to modest reduction in cocaine binding or transport, consistent 
with indirect effects on the active site structure.  Several mutations that affect cocaine 
affinity do so by inhibiting ion-binding or ion-transport conformational changes rather by 
directly affecting ligand- or DA-binding sites (Chen, Rickey et al. 2004; Chen, Zhen et al. 
2004; Loland, Granas et al. 2004).  D79 was the first DAT residue shown to be critical 
for transport (Kitayama, Shimada et al. 1992).  This residue is conserved in NSSs, and its 
mutation also strongly inhibits cocaine binding.  Its importance for transport and inhibitor 
binding has been supported by similar results from SERT (Barker, Moore et al. 1999) and 
by the finding that the analogous residue is present in the LeuTAa Na+ binding site 
(Yamashita, Singh et al. 2005).  D79 is suggested to be present within the DAT active 
site and compensates for the lack of a negative charge on DA by coordinating one of the 
cotransported Na+ ions (Wang, Sonders et al. 2003; Yamashita, Singh et al. 2005).  A 
nearby TM 1 residue F76 is indicated to be involved in constructing the active site, given 
the observation that mutation of this residue result in lowered cocaine affinity (Lin, Wang 
et al. 1999).  This residue corresponds to N21 in LeuTAa, which participates in substrate 
binding (Yamashita, Singh et al. 2005), and Y95 in SERT, which is implicated in 
substrate and ligand binding (Henry, Adkins et al. 2003; Henry, Field et al. 2006). These 
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data support the importance of this position in the NSS binding pocket.  V152 in TM 3 
also has good support for direct involvement in transport and cocaine binding, based on 
chimeric switches, multiple substitution analysis, and homology to a SERT inhibitor 
contact point at I172 (Henry, Adkins et al. 2003; Henry, Field et al. 2006) and a LeuTAa 
leucine contact point at V104 (Lee, Chang et al. 2000).  F319 and G323 of rDAT within 
TM 6, analogous to LeuTAa active-site phenylalanine and serine residues, cause the loss 
of essential all transport activity when mutated, consistent with roles in transport.   
Simultaneous mutation of three TM2 residues, L104, F105, and A109, leads to 
loss of cocaine binding with maintenance of DA transport (Wu and Gu 2003; Chen, Han 
et al. 2005).  However, LeuTAa structure and SCAM (substituted cysteine accessibility 
method) analysis of DAT (Sen, Shi et al. 2005) support the interpretation that this TM is 
found outside the active-site core and acts as a structural support for TM6, suggesting the 
likelihood that the TM2 mutations affect cocaine binding indirectly by leading to 
misalignment of TM6.  These studies highlight the importance of the overall transporter 
structure in maintenance of proper function, the apparent ease with which indirect effects 
can be transmitted to active site, and the challenges in determining DAT structure-
function relationships from mutagenesis. 
Several residues involved in conformational changes occurring during the 
translocation cycle have also been identified.  Mutations at W84, K264, D313, Y335, 
D345 and D346 result in loss of transport activity and alterations in cocaine binding 
(Chen, Rickey et al. 2004; Chen, Zhen et al. 2004; Loland, Granas et al. 2004).  Analysis 
of the ionic and Zn2+ dependence of these mutants suggest that the mutations suppress 
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transport by stabilizing particular structures of the protein, indicating that the wild-type 
residues participate in intermolecular interactions necessary for conformational 
rearrangements during the transport cycle.  In these studies it was also found that DATs 
locked in outward-facing conformations displayed increased cocaine affinity, whereas 
those locked in inward-facing conformations displayed decreased cocaine affinity (Chen, 
Rickey et al. 2004; Chen, Zhen et al. 2004), consistent with the cocaine-binding pocket 
being formed by an extracellular-facing form of the protein.  
SCAM study, determining the sensitivity of endogenous and exogenous cysteine 
residues to reactivity with sulfhydryl-modifying reagents, has also been used for studying 
the DAT structure and function.  By utilizing this approach, aqueously accessible regions 
in interhelical loops, DA or ligand access pathways, and non-accessible regions adjacent 
to membrane lipids or other protein structure could be identified.  To date, data from 
SCAM studies confirm the 12 TM topology of the DAT, which is consistent with other 
research results.  Furthermore, SCAM has also been used to detect conformational 
changes in the DAT.  Some residues are reveled to be involved in DA transport and 
cocaine binding, including C90, R219, C342, M371 and D436 (Ferrer and Javitch 1998; 
Chen, Ferrer et al. 2000; Norregaard, Loland et al. 2003).  
5. LeuTAa and DAT 
One of the major challenges to understanding how the DAT and related 
neurotransmitter transporters function has been the limited knowledge of the protein 
structure.  The sites of action for DA and ions, the nature of the conformational 
rearrangements that drive transport and the mechanisms by which cocaine and other 
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blockers bind to DAT and prevent transport are poorly understood.  None of the NSS 
proteins has been crystallized, and there is currently only limited experiment evidence 
pertaining to their 3-D structures.  In 2005, a breakthrough in this area was the 
determination of a high-resolution crystal structure of LeuTAa, a Na+-dependent bacterial 
leucine transporter (Yamashita, Singh et al. 2005).  Although only distantly related in 
amino acid sequence, this transporter is functionally homologous to the NSSs, and it is 
currently expected to provide an important template for interpretation and direction of 
DAT structure-function studies. 
In LeuTAa, TMs 1 to 5 and 6 to 10 form structural cassettes oriented to each other 
by a pseudo 2-fold axis, with TMs 1, 3, 6 and 8 forming a central core that creates a 
binding pocket for leucine and Na+.  The leucine- and Na+- binding sites are found about 
half way across the membrane and are in close proximity, consistent with a substrate 
moving as a unit.  In the crystallized structure, these binding sites are occluded from the 
aqueous medium by the external and internal gates, suggesting that the transport 
mechanism involves a minimum of three conformations: outward-facing, occlude and 
inward-facing.  High-resolution crystallographic studies of LeuT in complex with 
multiple tricyclic antidepressants (TCAs) showed that one TCA molecule bound at the 
base of the extracellular vestibule, further occluding leucine and the two sodium ions 
(Singh, Yamashita et al. 2007; Zhou, Zhen et al. 2007).  The location of the TCA 
molecule indicates an inhibitor binding site (secondary substrate site, S2) distinguished 
from the primary leucine binding site (S1).   
37 
 
A 3-D DAT model based on LeuTAa crystal structure also identified two similar 
binding sites (Indarte, Madura et al. 2008; Shi, Quick et al. 2008; Quick, Winther et al. 
2009).  S2 site for the DAT is located several angstroms to the extracellular side of the S1 
site, serving as a substrate staging area prior to passage through the external gate (Indarte, 
Madura et al. 2008; Shi, Quick et al. 2008).  Unlike TCA binding in LeuTAa, cocaine and 
benztropine are believed to bind in the S1 site (Beuming, Kniazeff et al. 2008; Bisgaard, 
Larsen et al. 2011). 
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II. MATERIALS AND METHODS 
A. Materials and Equipment 
1. Facilities 
Laboratories – Mellon Hall of Science, Room 408, 414, 456,   457 and 459 
2. Cell lines 
Murine neuroblastoma (N2A) cells stably expressing wildtype rat DAT 
N2A cells 
COS 7 (African green monkey kidney) cells 
3. Chemicals and Drugs 
Fetal bovine serum 
Thermo Scientific, Logan, UT 
Dulbecco’s Modified Eagle Medium (DMEM) 
Thermo Scientific, Logan, UT 
Opti-MEM I Reduced Serum Medium 
Invitrogen, Carlsbad, CA 
Dulbecco’s Phosphate Buffered Saline (DPBS) Ca/Mg-free 
Cambrex Bioscience Walkersville Inc., MD 
G-418 sulfate 
Clontech Laboratories Inc., CA 
L-Glutamine 
Invitrogen, Carlsbad, CA 
Penicillin-Streptomycin 
Gibco-BRL, Grand Island, NY 
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Compressed carbon dioxide 
Air Products, Pittsburgh, PA 
Ampicillin sodium salt 
Acros, NJ 
 
Trypsin-EDTA 10X 
Gibco-BRL, Grand Island, NY 
 
[3H]-Dopamine 
Perkin Elmer, Foster City, CA 
 
[3H]-WIN 35, 428 
Perkin Elmer, Foster City, CA 
 
Acetic acid, glacial 
Fisher Scientific, Pittsburgh, PA 
 
Agarose 
Invitrogen Corporation, Carlsbad, CA 
 
Bio-Rad protein assay dye reagent concentrate 
Bio-Rad Laboratories Inc., Hercules, CA 
 
Bovine serum albumin 
Sigma Chemical Co., St. Louis, MO 
 
Calcium chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
D-(+)-Glucose 
Sigma-Aldrich Co., St. Louis, MO 
 
dNTP mix 
Stratagene, La Jolla, CA 
 
DH5α cells 
Invitrogen, Carlsbad, CA 
 
Dimethylsulfoxide (DMSO) 
Sigma Chemical Co., St. Louis, MO 
 
EcoR1 
Invitrogen, Carlsbad, CA 
 
EDTA 
Sigma-Aldrich Co., St. Louis, MO 
 
Ethanol 200 proof 
Pharmaco Products Inc., Brookfield, CT 
 
40 
 
Ethanol, HPLC grade 
Acros, NJ 
 
Ethidium bromide 
Fisher Scientific, Pittsburgh, PA 
 
Glycerol 
Fisher Scientific, Pittsburgh, PA 
 
Glycine 
Sigma-Aldrich Co., St. Louis, MO 
 
HEPES free acid 
MP Biomedicals Inc., Solon, OH 
 
HBSS/modified 
Hyclone, Logan, UT 
 
Isopropanol (DNase, RNase and protease free) 
Fisher Scientific, Pittsburgh, PA 
 
LB agar 
Fisher Scientific, Pittsburgh, PA 
 
LB broth 
Fisher Scientific, Pittsburgh, PA 
 
MAB369 Rat anti-Dopamine Transporter 
Chemicon International, Temecula, CA 
 
Methanol, HPLC grade 
Fisher Scientific, Pittsburgh, PA 
 
Paraformaldehyde 
Sigma Chemicals Co., St. Louis, MO 
 
TransIT-LT1 Transfection Reagent 
Mirus Coporation, Madison, WI 
 
Polymerase, Pfu Turbo 
Stratagene, La Jolla, CA 
 
Potassium chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Potassium phosphate, monobasic 
Sigma Chemical Co., St. Louis, MO 
 
Primers 
Operon, Huntsville, AL 
 
RNase A (DNase free) 
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Fisher Scientific, Pittsburgh, PA 
 
SOC media 
Invitrogen, Carlsbad, CA 
 
ScintiSafe scintillation fluid 
Fisher Scientific, Pittsburgh, PA 
 
Sodium Chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Sodium Hydroxide 
Fisher Scientific, Pittsburgh, PA 
 
Sodium Hydroxide 2N solution 
Fisher Scientific, Pittsburgh, PA 
 
Sodium Hydroxide 12N solution 
Fisher Scientific, Pittsburgh, PA 
 
Sodium lauryl sulfate 
Sigma Chemical Co., St. Louis, MO 
 
T4 DNA ligase 
Invitrogen, Carlsbad, CA 
 
Tris-EDTA buffer (DNase, RNase and protease free) 
Acros, NJ 
 
Tris free base 
Fisher Scientific, Pittsburgh, PA 
 
Tris-HCl salt 
Sigma Chemical Co., St. Louis, MO 
 
Triton X-100 
Acros, NJ 
 
PshAI 
New England Biolabs, Ipswich, MA 
 
BsiWI 
New England Biolabs, Ipswich, MA 
 
Clomipramine hydroxide 
Tocris bioscience, Elllisville, MO 
 
Benztropine methane-sulfonate 
Sigma Chemical Co., St. Louis, MO 
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4. Materials 
Cell culture flasks, 75cm2 
Corning Inc., Teterboro, NY 
 
Cell culture grade water 
Hyclone, Logan, UT 
 
Cell culture plates (10, 25cm) 
Fisher Scientific, Pittsburgh, PA 
 
Centrifuge tube, 15ml 
Corning Inc., Horseheads, NY 
 
Centrifuge vials, 1.5ml 
Corning Inc., Horseheads, NY 
 
Culture tubes, disposable 
Fisher Scientific, Pittsburgh, PA 
 
Falcon tubes, 14ml 
Fisher Scientific, Pittsburgh, PA 
 
Falcon tubes, 50ml 
Fisher Scientific, Pittsburgh, PA 
 
Filter unit, sterile 
Millipore, Billerica, MA 
 
Eppendorf microcentrifuge tubes, 1.5 ml 
Fisher Scientific, Pittsburgh, PA 
 
Parafilm 
Fisher Scientific, Pittsburgh, PA 
 
Pasteur pipettes, disposable 
Fisher Scientific, Pittsburgh, PA 
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Pipette tips, disposable Redi-Tips TM (1, 10, 200, 1000 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Polaroid film 
Fisher Scientific, Pittsburgh, PA 
 
Polypropylene tubes 
Fisher Scientific, Pittsburgh, PA 
 
Respirator 
Fisher Scientific, Pittsburgh, PA 
 
Scintillation vials 
Fisher Scientific, Pittsburgh, PA 
 
Serological pipettes, sterile disposable (5, 10, 25 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Syringes, sterile (10 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Thermowell PCR tubes 
Corning,  Horseheads, NY 
 
Tissue culture plates, sterile (6 well, 24 well) 
Fisher Scientific, Pittsburgh, PA 
Sarstedt Inc., Newton, NC 
 
 
Kits 
Gel extraction kit 
Qiagen Inc., Valencia, CA 
 
PCR purification kit 
Qiagen Inc.,Valencia, CA 
 
Plasmid miniprep kit 
Stratagene, La Jolla, CA 
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Plasmid maxiprep purification kit 
Qiagen Inc.,Valencia, CA  
5. Equipment 
Analytical balance 
Mettler Toledo Inc., OH 
 
Weighing scale 
Denver Instruments Co., CO 
 
Bottletop dispenser 
Brinkmann Instruments Inc., NY 
 
Cell culture incubator 
Forma Scientific, MA 
 
Centrifuge Model 228 
Fisher Scientific, Pittsburgh, PA 
 
Centrifuge 5415 C 
Eppendorf Scientific Inc., NY 
 
Centrifuge 5810 R 
Eppendorf Scientific Inc., NY 
 
Confocal laser microscope Leica TCS-SP2 
Leica Microsystems Inc., PA 
 
Dispensing Eppendorf pipetter (50 ml) 
Brinkmann Instruments Inc., NY 
 
Electrophoresis Power Supply 
Life Technologies Inc., Gaithersburg, MD 
 
Horizontal Gel Electrophoresis System 
Life Technologies Inc., Gaithersburg, MD 
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Inverted microscope Olympus CK40 
Fisher Scientific, Pittsburgh, PA 
 
Isotemp Incubator 
Fisher Scientific, Pittsburgh, PA 
 
Lab freezers and refrigerators 
Forma Scientific, MA 
 
Liquid Nitrogen tank 
Liquid Scintillation Analyzer 
Packard Instruments Co., CT 
 
Millipore Milli-Q and Elix 
Millipore Corporation, MA 
 
Mixer (Style: 37600) 
Thermolyne Corporation, IA 
 
NapFLOW Laminar air flow unit 
Fisher Scientific, Pittsburgh, PA 
 
ORBIT Shaker 
Lab-line Instruments Inc., IL 
 
PCR Mastercycler 
Eppendorf Scientific Inc., NY 
 
pH meter AB15 
Fisher Scientific, Pittsburgh, PA 
 
Pipet-aid 
Drummond Scientific Co., Broomall, PA 
 
Pipetman (P-2, P-10, P-20, P-100, P-200, P-1000) 
Mettler Toledo Company, Woburn, MA 
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Polaroid Gelcam 
Polaroid Corporation, Cambridge, MA 
 
Stir plate Nuova II 
Thermolyne Corporation, IA 
 
Universal Vacuum System UVS 400 
Savant Instruments Inc., NY 
 
Vacuum pressure pump  
Barnant Co., IL 
 
UV Transilluminator M-26 
UVP Inc., Upland, CA 
 
UV-Visible Spectrophotometer DU 530 
Beckman Instruments Inc., Fullerton, CA 
 
Vertex-2 Genie 
Scientific Industries Inc., NY 
 
Water bath 180 series 
Precision Scientific, Winchester, VA 
 
Water bath Iso TEMP 205 
Fisher Scientific, Pittsburgh, PA 
 
6. Computer software 
GraphPad Prism 5.0 
GraphPad Software, San Diego, CA 
 
Adobe Acrobat Reader 7.0 
Adobe Systems Inc., San Jose, CA 
 
Adobe Acrobat Writer 
Adobe Systems Inc., San Jose, CA 
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ChemDraw Ultra 11.0 
CambridgeSoft Corporation, Cambridge, MA 
 
Microsoft Office Word & Excel 2003 
Microsoft Corporation, Seattle, WA 
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B. Methodology and Procedures 
1. Cell culture 
COS-7 cells and N2A cells were employed for experiments requiring transient 
transfection of plasmid DNA.  COS-7 cells were maintained in DMEM media 
supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 units/ml 
streptomycin and 20 mM L-glutamine.  The N2A cell line employed in the study were 
kindly provided by Dr. Margaret E. Gnegy’s laboratory, University of Michigan, MI.  
The cells were grown in Opti-MEM media supplemented with 10% FBS, 100 units/ml 
penicillin and 100 units/ml streptomycin.   N2A cells stably transfected with WT DAT 
were cultured in Opti-MEM media supplemented with 10% FBS, 100 units/ml penicillin,  
100 units/ml streptomycin  and 450 µg/ml G418.  All cell types were grown as 
monolayers in 75 cm2 flasks at 37ºC and 5% CO2 and subcultured twice weekly or every 
3 days.  For subculturing the COS-7 cells, the exhausted media in the flask was aspirated 
and the confluent adherent cells were washed once with 10 ml Hanks buffered salt 
solution (HBSS).  The cells were then detached by addition of 3ml trypsin-EDTA 
solution to the monolayer.  The trypsin-EDTA solution was swirled to coat the monolayer 
and 2 ml of the trypsin-EDTA was aspirated from the flask.  The flask was then returned 
to the incubator for 3 min or until the cells detached from the flask.  The detached cells 
were resuspended in 9 ml complete media to quench the trypsinization reaction.  Two ml 
of the cell suspension was transferred into a new labeled flask containing 18 ml of 
complete media.  The flask was capped and the cells evenly suspended by gently swirling 
the flask.  The flask was placed in the incubator and the cells were allowed to grow till 
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the next subculture.  For subculturing the N2A and WT DAT N2A cells, the exhausted 
media in the flask was aspirated and the confluent adherent cells were washed with 10 ml 
HBSS.  To detach the cells from the flask, 3 ml of trypsin-EDTA was added and swirled 
to cover the cell monolayers, and then 2 ml of the trypsin-EDTA was aspirated.   When 
the cells were detached from the flask, 9 ml of complete Opti-MEM media was added to 
inactivate the trypsin-EDTA.  The cell suspension was transferred into a 15 ml tube and 
centrifuged at 1000g for 5 minutes.  The supernatant was decanted and cell pellet was 
resuspended in 10 ml complete Opti-MEM media.  Two ml of the cell suspension was 
then transferred into a new labeled flask containing 18 ml of complete fresh Opti-MEM 
media.  The flask was tightly capped and then gently swirled to evenly suspend the cells.  
The flask was placed in the incubator and the cells were allowed to grow until the next 
subculture. 
2. Site-directed mutagenesis 
All site-directed mutagenesis was conducted using the QuickChange mutagenesis 
kit (Stratagene).  rDAT in Bluescript vector was used as template for the polymerase 
chain reaction (PCR)-based mutagenesis.  Sense and antisense oligonucleotides were 
designed to contain the desired mutations.  The oligonucleotide primers were synthesized 
by Operon Biotechnologies Inc., Huntsville, AL, U.S.A.  Sixteen mutants were designed 
and generated: Y88A, R85D, D475R, R85D/D475R, K92D, D312K, K92D/D312K, 
D384A, D384N, G425I, I468C, I468A, T472A, T472K, H476A and F542A.  The 
sequences of primers used for the generation of Y88A DAT were: 5’-
GTCTGGAGGTTTCCCGCCCTGTGCTACAAAAATG-3’ for the forward primer and 
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5’-CATTTTTGTAGCACAGGGCGGGAAACCTCCAGAC-3’ for the reverse primer.  
The sequences of primers designed for R85D DAT were: 5’-
CTGGCCAATGTCTGGGATTTTCCCTACCTGTGC-3’ for the forward primer and 5’-
GCACAGGTAGGGAAAATCCCAGACATTGGCCAG-3’ for the reverse primer.  The 
sequences of primers used for the generation of D475R DAT were: 5’-
GTCTCACACTGCTGCGCCACTTTGCAGCTGGCACA-3’ for the forward primer and 
5’-TGTGCCAGCTGCAAAGTGGCGCAGCAGTGTGAAGAC-3’ for the reverse 
primer.  The primers for generating R85D DAT and D475R DAT were also employed to 
generate switch mutant R85D/D475R DAT.  The sequences of primers used for the 
generation of K92D DAT were: 5’-
GTTTCCCTACCTGTGTGCTACGATAATGGTGGAGGTGCCTTC-3’ for the forward 
primer and 5- GAAGGCACCTCCACCATTATCGTAGCACAGGTAGGGAAAC-3’ for 
the reverse primer.   The sequences of primers used for the generation of D312K DAT 
were: 5’-GCATCTGTGTGGATCAAAGCTGCCACCCAGGTGT-3’ for the forward 
primer and 5’-CACCTGGGTGGCAGCTTTGATCCACACAGATGCCTC-3’ for the 
reverse primer.  The primers for generating K92D DAT and D312K DAT were also 
employed to generate switch mutant K92D/D312K DAT.  The sequences of primers used 
for the generation of D384A DAT were: 5’-
 CAGAGATGTGGCCACAGCTGGACCTGGGCTCATC-3’ for the forward primer and 
5’-GATGAGCCCAGGTCCAGCTGTGGCCACATCTCTG-3’ for the reverse primer.   
The sequences of primers used for the generation of D384N DAT were: 5’- 
CAGAGATGTGGCCACAAATGGACCTGGGCTCATC-3’ for the forward primer and 
5’-GATGAGCCCAGGTCCATTTGTGGCCACATCTCTG-3’ for the reverse primer.  
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The sequences of primers used for the generation of G425I DAT were: 5’- 
GTATCGACAGTGCAATGGGGATCATGGAGTCAGTG-3’ for the forward primer 
and 5’- CACTGACTCCATGATCCCCATTGCACTGTCGATAC-3’ for the reverse 
primer.  The sequences of primers used for the generation of I468C DAT were: 5’-
GTCACCAACGGTGGCTGCTACGTCTTCACACTG-3’ for the forward primer and 5’- 
CAGTGTGAAGACGTAGCAGCCACCGTTGGTGAC-3’ for the reverse primer.  The 
sequences of primers used for the generation of I468A DAT were: 5’- 
GTCACCAACGGTGGCGCCTACGTCTTCACACTG-3’ for the forward primer and 5’- 
CAGTGTGAAGACGTAGGCGCCACCGTTGGTGAC-3’ for the reverse primer.  The 
sequences of primers used for the generation of T472K DAT were: 5’- 
GTGGCATCTACGTCTTCAAACTGCTGGACCACTTTGC-3’ for the forward primer 
and 5’- GCAAAGTGGTCCAGCAGTTTGAAGACGTAGATGCCAC-3’ for the reverse 
primer.  The sequences of primers used for the generation of T472A DAT were: 5’- 
GTGGCATCTACGTCTTCGCACTGCTGGACCACTTTGC-3’ for the forward primer 
and 5’- GCAAAGTGGTCCAGCAGTGCGAAGACGTAGATGCCAC-3’ for the reverse 
primer.  The sequences of primers used for the generation of H476A DAT were: 5’-
GTCTTCACACTGCTGGACGCCTTTGCAGCTGGCACATC-3’ for the forward primer 
and 5’-GATGTGCCAGCTGCAAAGGCGTCCAGCAGTGTGTGAAG-3’ for the 
reverse primer.  The sequences of primers used for the generation of F542A DAT were: 
5’-CAGCATTGTGACCGCCAGACCCCCACACTAT-3’ for the forward primer and 5’-
ATAGTGTGGGGGTCTGGCGGTCACAATGCTG-3’ for the reverse primer.  These 
complementary primers were annealed to the template cDNA and extended with the 
proofreading polymerase pfu Turbo (Stratagene) with the following PCR parameters:  
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denaturation of the double stranded template DNA 30 seconds at 95ºC, annealing of the 
primers to the single stranded DNA 1 minute at 55ºC and extension of the new DNA 
strand 6 minutes at 68ºC for 25 cycles.  Subsequently, the PCR product was digested with 
Dpn I to eliminate the methylated and hemimethylated, nonmutated parental DNA 
strands.  The mutated cDNA was then transformed into XL1-Blue supercompetent E. coli 
cells using the heat-shock method.  The bacterial cell solution was then plated on agar 
plates containing 50 µg/ml ampicillin and incubated overnight (~16 hours) at 37 ºC.  The 
following day, colonies were selected and plasmid preparation was carried out using the 
Stratagene miniprep system to produce pure supercoiled plasmid DNA.  Mutagenesis was 
confirmed by DNA sequencing analysis of the miniprep product (University of Pittsburgh 
sequencing facility).  The fragment (~1800 bp) containing the mutation in rDAT-
pBluescript was isolated by double digestion with PshAI and BsiWI restriction enzymes, 
gel purified, and ligated into the PshAI/BsiWI digested rDAT-pIRES vector.  The ligation 
product was transformed into DH5α supercompetent cells by heat shock method and the 
cells were plated on ampicillin supplemented agar plates.  The agar plates were then 
incubated overnight (~16 hours) at 37ºC to allow growth of bacterial colonies.  A few 
bacterial colonies were again selected and used to inoculate 5 ml of LB broth for 16 hours.  
The plasmid DNA was then purified using the Stratagene mini-prep kit.  The presence of 
supercoiled plasmid DNA was verified by agarose gel electrophoresis.  Following 
confirmation of successful mutagenesis by DNA sequence analysis, 200 ml LB broth was 
inoculated to produce large amounts of the plasmid DNA of interest.  Plasmid 
preparations were carried out using the Qiagen maxi-prep kit to produce a larger volume 
of pure supercoiled plasmid DNA sufficient for transient transfection of cells.  The DNA 
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concentration and purity (measured as A260:A280 ratio) were estimated through UV 
spectrophotometic analysis.  Plasmid DNA with a ratio of greater than or equal to 1.7 was 
typically used for transient transfection of mammalian cells. 
3. Cell Transfections 
A modification of the calcium phosphate method or the use of TransIT-LT1 
reagent (Mirus, Madison, WI) was employed for transient transfection of COS 7 and 
N2A cells.  For the calcium phosphate method, confluent cells were subcultured in 6-well 
or 24-well plates such that the monolayer would be 40 - 50% confluent when the 
transfection commenced the next day.  Four hours prior to transfection, the media in the 
wells was replaced with fresh media.  All the reagents were filter-sterilized.  The 
transfection procedure involved preparing 2 tubes, with the contents of one tube added 
slowly to the other one.  The first tube contained Millipore water, plasmid DNA, 10х 
Tris-EDTA (TE) buffer pH 8.0 and 0.5 M CaCl2 mixed together to achieve a final amount 
of DNA of 20 µg.  The second tube contained 2x HEPES – buffered saline (HBS) 
solution.  The contents of first tube were added to the second tube dropwise with 
continuous gentle vortexing and incubated at room temperature.  Soon after the DNA 
complexes started forming, the mixture was pipetted up and down thrice to ensure a 
uniform suspension and to reduce the particle size of the complexes.  For an individual 
well of the 6-well plate, 200 µl of the above mixture was added, while 100 µl of the 
mixture was added to a single well of 24-well plate.  The cells take up the exogenous 
plasmid via endocytosis of the calcium phosphate/DNA complex.  After addition of the 
mixture, the plate was gently swirled to ensure uniform distribution.  The following day, 
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the transfection mixture in each well was replaced with fresh media.  The cells were used 
for the pharmacological studies 48 hours after transfection.   
For the TransIT-LT1 reagent-mediated transient transfection, following the 
manufacturer’s protocol, N2A cells were seeded in 24-well plates at a concentration of 1 
- 3 x 105 cells/well (the monolayer would be 50 -70% confluent) approximately 24 hours 
before transfection.   On the day of transfection, TransIT-LT1 reagent-DNA complex was 
prepared immediately before transfection.  TransIT-LT1 reagent was first warmed up to 
room temperature and vortexed gently before using.  For preparing the transfection 
mixture for the cells in one well, 1.5 µl TransIT-LT1 reagent was added to 50 µl serum-
free medium in a sterile tube and mixed by gently pipetting.  Plasmid DNA (0.5 µg) was 
then added to the diluted TransIT-LT1 reagent, mixed by gently pipetting and incubated 
for 15 - 30 minutes at room temperature to allow complex formation.    Total volume of 
the transfection mix was transferred to the cells in a single well and the plate was gently 
swirled to ensure even distribution of the complexes.  The cells were used for 
pharmacological assays 48 hours after transfection.  When performing transient 
transfections of cells in more than one well, all the volumes were scaled up appropriately. 
4. [3H]-Dopamine uptake assays 
[3H]-dopamine uptake assays were conducted with cell monolayers seeded in 6-
well or 24-well plates.  For performing simple [3H]-dopamine uptake assays, cell 
monolayers were washed 2 х 1 ml with “KRH buffer” (25 mM HEPES, pH 7.3, 125 mM 
NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose) 
supplemented with 50 mM ascorbic acid (KRH/AA), and then incubated with 750 µl (6-
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well plate) or 375 µl (24-well plate) KRH/AA buffer (total uptake) or 10 µM mazindol 
(non-specific uptake) for 10 minutes, followed by incubation with 10 nM [3H]-dopamine 
for an additional 5 minutes.  Uptake was quenched by washing the cell monolayers 2 х 1 
ml with KRH/AA buffer.  Subsequently, cells in each well were lysed with 1 ml of 1% 
SDS, incubated at room temperature for 1 hour with gentle shaking.  The cell lysates 
were transferred into scintillation vials containing 5 ml of ScintiSafe fluid and the 
incorporated radioligand was determined by employing a liquid scintillation counter.  The 
specific uptake was calculated as the difference between total and non-specific uptake, i.e. 
uptake in the presence and absence of 10 µM mazindol. 
For performing [3H]-dopamine uptake inhibition assays, the cell monolayer was 
washed twice with KRH/AA buffer (2 x 1 ml), incubated with inhibitors for 10 minutes, 
followed by the addition of 10 nM [3H]-dopamine for a further 5 minutes.  The uptake 
inhibition assays included nonradioactive DAT inhibitors at the following concentration 
ranges: cocaine, 1 nM – 100 µM; benztropine, 0.1 nM – 30 µM.  Uptake was quenched 
by aspirating the inhibitor/radioligand solution and washing the cell monolayer 2 х 1 ml 
with KRH/AA buffer.  Non-specific uptake was determined by using 10 µM mazindol.  
The cells in each well were then lysed by incubating with 1 ml of 1% SDS at room 
temperature for 1 hour with gentle shaking.  The cell lysate was transferred into 
scintillation vials containing 5 ml of ScintiSafe fluid and radioactivity was counted using 
a liquid scintillation counter.  The specific uptake was calculated as the difference 
between total and non-specific uptake.  The IC50 values for [3H]-dopamine uptake 
inhibition were determined with GraphPad Prism 5.0. 
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5. [3H]-WIN35,428 saturation binding assays 
All binding assays were conducted with cells subcultured in 24-well plates.   [3H]-
WIN35,428, an analog of cocaine, was the radioligand used in all binding assays because 
it is more stable in vitro.  For [3H]-WIN35,428 saturation binding assay, serial dilutions 
of WIN35,428 (1 nM – 10 µM) were made in KRH/AA buffer.  [3H]-WIN35,428 was 
added to each dilution of drug to achieve a final concentration of approximately 1 nM for 
the radioligand.  Cell monolayers were washed with 2 х 1 ml KRH/AA buffer and 
incubated with the mixture of [3H]-WIN35,428 and WIN35,428 for 15 minutes.  The 
drug solution was then aspirated and the cell monolayers were washed with 2 х 1 ml 
KRH/AA buffer.  Cells were lysed with 1% SDS solution and the radioactivity of the cell 
lysate was determined in a scintillation counter.   Bmax and Kd values for [3H]-WIN35,428 
binding were determined with GraphPad Prism 5.0.   
6. [3H]-WIN35,428 binding inhibition assays 
All competition binding assays were conducted exactly as described for the 
dopamine uptake inhibition assays except that [3H]-dopamine was replaced with 1 nM 
[3H]-WIN 35,428 and cells were incubated with a mixture of radioligand and the 
nonradioactive competitor for 15 minutes.  Serial dilutions of the drugs to be examined 
were made in KRH/AA buffer.  [3H]-WIN 35,428 was added to each dilution of drug to 
achieve a final concentration of 1 nM for the radioligand.  The ranges of concentrations 
of drugs employed were as indicated above for dopamine uptake inhibition assays: 
cocaine, 1 nM – 100 µM; benztropine, 0.1 nM – 30 µM.  Cell monolayers were washed 
with 2 х 1 ml KRH/AA buffer and incubated with the mixture of [3H]-WIN35,428 and 
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the nonradioactive competitor for 15 minutes.  The experiment was quenched by 
removing the drug solution and washing the cell monolayers with 2 х 1 ml KRH/AA 
buffer.  Non-specific binding was assessed by using 10 µM mazindol.  Cells were then 
lysed with 1 ml of 1% SDS solution and incubated at room temperature for 1 hour with 
gentle shaking.  Cell suspensions from each well were then transferred to scintillation 
vials containing 5 ml of ScintiSafe fluid and radioactivity was counted using a 
scintillation counter.  The Ki values were determined with GraphPad Prism 5.0 software. 
7. Protein assays 
COS-7 and N2A cells transiently transfected with WT or mutated DAT were used 
for protein assays.  For every experiment carried out that required protein content 
estimation, two wells were reserved for this purpose.  The protein assays were performed 
as follows: the confluent cell monolayers were washed 2 x 1 ml with PBS, cells in each 
well were lysed with 0.5 ml 0.2 N NaOH solution, gently scraped with a rubber cell 
scraper and incubated at 4ºC with gentle shaking for 30 min.  The cell lysates were 
transferred into Eppendorf tubes for storage at -20ºC or for immediate protein estimation 
via Bradford assay.  For each assay, carried out in duplicate, 750 µl of water was added 
to 50 µl of cell lysate in a test tube and mixed gently.  200 µl of BioRad reagent was then 
added to the cell solution, vortexed for 10 sec, and incubated at room temperature for 10 
min.  The absorbance of the protein/dye solution was measured at 595 nm using a UV-
visible wavelength spectrophotometer.  The concentration of protein was calculated by 
interpolating the absorbance reading of the sample protein using a protein standard curve.  
Bovine serum albumin (BSA; 1 mg/ml stock solution) was used as the protein standard 
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for generating the standard curve.  A serial dilution of the BSA stock solution in sterile 
water was performed to make six different concentrations of BSA such that final 
concentrations were 1, 2, 3, 4, 5 and 6 µg/ml.  The initial volume for each dilution was 
800 µl (e.g., for 6 µg/ml: 6 µl of 1 mg/ml BSA + 794 µl of sterile water).  BioRad reagent 
was then added to each test tube containing the protein dilutions, vortexed for 10 sec, and 
incubated at room temperature for 10 min.  The absorbance of each protein dilution was 
read at 595 nm.  A protein standard curve was generated using Microsoft Excel by 
plotting of absorbance versus amount of protein.   
8. Data analysis 
Statistical significance was calculated using GraphPad Prism 5.0.  Statistical 
significance between two groups was determined using a two-tail Student’s t test, while 
comparison among more than two groups used one-way analysis of variance with 
Newman-Keuls post hoc test.   
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III. RESULTS AND DISCUSSION 
A. Pharmacological characterization of DAT mutants 
1. Results 
Wildtype (WT) DAT and sixteen DAT mutants (R85D, D475R, R85D/D475R, 
K92D, D312K, K92D/D312K, Y88A, D384A, D384N, G425I, I468C, I468A, T472A, 
T472K, H476A and F542A) were first screened for their abilities to bind [3H]-
WIN35,428 and take up [3H]-dopamine.  The mutant DATs were made by site-directed 
mutagenesis and confirmed by DNA sequencing.  All DAT mutants were initially 
assessed in parallel to WT DAT via one point [3H]-WIN35,428 binding and [3H]-
dopamine uptake assays.  Relative to WT DAT, twelve DAT mutants (R85D, 
R85D/D475R, K92D, H476A, Y88A, F542A, T472K, T472A, D384A, D384N, I468C 
and I468A) displayed detectable specific binding of [3H]-WIN35,428, whereas ten 
mutated DAT proteins (K92D, H476A, Y88A, F542A, T472K, T472A, D384A, D384N, 
I468C and I468A) displayed functional uptake of [3H]-dopamine (Fig. 12).  Net binding 
of [3H]-WIN35,428 was decreased (around 70% loss) or eliminated by the single R85D 
or D475R mutations.  The switch mutant R85D/D475R restored net binding of the 
radioligand to above WT DAT levels (Fig. 12, upper panel), while none of these three 
DAT mutants displayed specific uptake of [3H]-dopamine (Fig. 12, lower panel).  Net 
binding of K92D DAT was decreased by around 85%, while D312K DAT and switch 
mutant K92D/D312K displayed no detectable binding (Fig. 12, upper panel).  Specific 
uptake of [3H]-dopamine (around 15% of the WT DAT) was only observed for K92D 
among these three DAT mutants (Fig. 12, lower panel).  The specific binding and uptake 
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was eliminated by the G425I mutation (Fig. 12).  Net binding of [3H]-WIN35,428 was 
similar to WT DAT at mutants H476A, Y88A, F542A, T472K, T472A, D384A, D384N 
and I468A.  Mutant I468C displayed decreased net binding by 80% compared to WT 
DAT (Fig. 12, upper panel).  T472K and I468A displayed decreased uptake ability by 
30%, while 70% loss of uptake ability was observed at mutation I468C.  Meanwhile, 
specific uptake of [3H]-dopamine at mutants H476A, Y88A, F542A, T472A, D384A and 
D384N was similar to WT DAT (Fig. 12, upper panel). 
61 
 
WT
R8
5D
D4
75
R
R8
5D
/D
47
5R
K9
2D
D3
12
K
K9
2D
/D
31
2K
H4
76
A
Y8
8A
F5
42
A
G4
25
I
T4
72
K
T4
72
A
D3
84
A
D3
84
N
I46
8C
I46
8A
0
25
50
75
100
125
150
175
200
225
250
 *
 *
 *
 *
 *  *  *
 *
Sp
ec
ifi
c 
[3
H
]-
W
IN
35
,4
28
 B
in
di
ng
 (%
 W
T 
D
A
T)
WT
R8
5D
D4
75
R
R8
5D
/D
47
5R
K9
2D
D3
12
K
K9
2D
/D
31
2K
H4
76
A
Y8
8A
F5
42
A
G4
25
I
T4
72
K
T4
72
A
D3
84
A
D3
84
N
I46
8C
I46
8A
0
25
50
75
100
125
150
 *  *  *
 *
 *  *  *
 *
 *
 *
Sp
ec
ifi
c 
[3
H
]-
do
pa
m
in
e 
up
ta
ke
 (%
 W
T 
D
A
T)
 
Figure 12.   Determination of [3H]-WIN35,428 specific binding and [3H]-dopamine 
uptake ability by COS-7 or N2A cells expressing WT or mutant DAT proteins. 
 The extent of specific [3H]-WIN35,428 binding (upper panel) and [3H]-dopamine 
uptake (lower panel) as a percentage of WT DAT was assessed for cells transiently 
transfected with plasmid encoding mutated DATs (R85D, D475R, R85D/D475R, K92D, 
D312K, K92D/D312K, Y88A, D384A, D384N, G425I, I468C, I468A, T472A, T472K, 
H476A and F542A).  The data represent an average of 3 separate experiments.  * P < 
0.05 (Student T test) relative to WT DAT. 
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Mutants with detectable binding or uptake were further characterized in parallel to 
WT DAT.  Kd and Bmax values for [3H]-WIN35,428 binding at each DAT mutant were 
derived from WIN saturation binding assays.  Bmax values reflect DAT expression at the 
cell surface as it has been shown that WIN 35,428 does not cross the plasma membrane 
of the intact cell appreciably (Chen, Zhen et al. 2004).  Relative to WT DAT, the affinity 
of WIN35,428 increased 8-fold at R85D DAT and 9-fold at R85D/D475R DAT.  
Measured by maximal [3H]-WIN35,428 binding (Bmax), the number of drug-accessible 
R85D DAT molecules was 10 fold lower than WT, while the R85D/D475R switch 
mutant was 2-fold lower than WT but 9-fold higher than R85D DAT.  The binding 
affinity of H476A-mutated DAT protein was not significantly different from WT DAT, 
whereas the number of drug-accessible protein molecules was 3-fold lower than WT 
DAT.   For the F542A, Y88A, T472A and T472K mutants, both the affinity of 
WIN35,428 and the number of drug-accessible DAT molecules were similar to WT DAT.  
D384A substitution decreased the affinity of WIN35,428 by 5-fold and the number of 
drug-accessible DAT molecules by 13-fold.  The D384N mutant displayed WT-like 
affinity for WIN35,428 and no change in the number of drug-accessible binding sites.  
I468C and I468A mutations did not alter the binding affinity; the numbers of drug-
accessible protein molecules for these two mutants were 30-fold and 2-fold lower than 
WT, respectively. 
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Table 1.  Affinity of WIN 35,428 at N2A neuroblastoma cells or COS 7 cells 
transiently expressing DAT constructs. 
 Kd and Bmax values were derived from experiments incubating transiently 
transfected cells with nonradioactive WIN35,428 in the presence of [3H]-WIN35,428 at 
room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least 
three independent experiments, each conducted in duplicate determinations. 
 
DAT Construct WIN35,428 
 Kd / nM Bmax (fmol/mg) 
WT 15 ± 2.1 1799 ± 316 
R85D 2.0 ± 0.6* 179 ± 49* 
R85D/D475R 1.7 ± 0.5* 720 ± 138* 
H476A 54 ± 14 529 ± 172* 
F542A 25 ± 4.7 1900 ± 216 
Y88A 17 ± 3.2 1723 ± 235 
T472A 11 ± 3.2 1240 ± 56 
T472K 23 ± 6.7 1355 ± 133 
D384A 73 ± 6.2* 142 ± 6.1* 
D384N 20 ± 2.8 1667 ± 366 
I468C 19 ± 8.5 60 ± 23* 
I468A 11 ± 1.9 918 ± 151* 
* P < 0.05 vs. WT DAT 
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Binding affinity (Ki) and dopamine uptake inhibition potency (DUIP) of cocaine 
were also characterized at DAT mutants in parallel to WT DAT.  The R85D mutation 
increased cocaine affinity by 23-fold, while the double mutation R85D/D475R increased 
cocaine affinity by 16-fold (Table 2).   The DUIP of cocaine at these two mutants was not 
assessed because neither displayed detectable dopamine uptake (Fig. 12).  H476A 
substitution displayed WT-like affinity and DUIP of cocaine.  The mutation F542A did 
not alter cocaine affinity, whereas the DUIP of cocaine was decreased 4-fold at this 
mutation.  Cocaine affinity at mutations Y88A, T472K and T472A was similar to WT 
DAT, while the DUIP of cocaine was decreased around 3-fold by these three mutations.  
D384A substitution decreased both cocaine affinity and DUIP by 3-fold and 6.5-fold, 
respectively; D384N mutant only affected cocaine affinity (3-fold loss).  Cysteine (C) 
substitution at I468 did not alter either affinity or DUIP of cocaine, while alanine (A) 
displacement at this position increased cocaine affinity 1.5-fold (Table 2).  The ratios of 
dopamine uptake inhibition potency to binding affinity for the different DAT mutants 
were also calculated (Table 2).    Ki and IC50 values for WT DAT were essentially 
identical (given ratio = 1).  H476A DAT displayed WT-like cocaine Ki and IC50 values).  
F542A, Y88A, T472K, T472A and D384A point mutations decreased the DUIP of 
cocaine 3-fold compared to the corresponding binding affinity of cocaine, whereas 
D384N substitution increased DUIP of cocaine 2-fold versus the binding affinity.  
Mutation at I468A decreased DUIP of cocaine by 2-fold relative to binding affinity, 
while I468C displayed the same binding affinity and DUIP of cocaine (Table 2). 
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Table 2.  Binding affinity and DUIP of cocaine at N2A neuroblastoma cells or COS 
7 cells transiently expressing DAT constructs. 
 Ki and IC50 values were determined from experiments incubating transiently 
transfected cells with cocaine in the presence of [3H]-WIN35,428 or [3H]-dopamine at 
room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least 
three independent experiments, each conducted in duplicate determinations.  Ratios were 
calculated using the IC50 values and Ki values. 
 
DAT Construct Cocaine 
 Ki / nM IC50 / nM DUIP (IC50)/Ki 
WT 214 ± 11 251 ± 27 1 
R85D 9.1 ± 1.3* ND ND 
R85D/D475R 13.3 ± 0.2* ND ND 
H476A 224 ± 35 312 ± 78 1 
F542A 339 ± 65 1023 ± 360* 3 
Y88A 210 ± 27 661 ± 60* 3 
T472A 264 ± 56 869 ± 85* 3 
T472K 259 ± 45 763 ± 163* 3 
D384A 589 ± 16* 1631 ± 43* 3 
D384N 622 ± 38* 282 ± 11 0.5 
I468C 251 ± 27 314 ± 45 1 
I468A 140 ± 19* 335 ± 46 2 
* P < 0.05 vs. WT DAT 
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Binding affinity (Ki) and DUIP of benztropine were assessed at DAT mutants in 
parallel to WT DAT.  The R85D mutation decreased benztropine affinity by 2.5-fold, 
while the double mutation R85D/D475R decreased benztropine affinity by 10-fold (Table 
3).   The DUIP of benztropine at these two mutants was not assessed because neither 
displayed detectable dopamine uptake (Fig. 12).  Mutants H476A, F542A and Y88A 
displayed WT-like affinity and DUIP of benztropine.  Benztropine affinity at mutant 
T472K was not appreciably altered compared to WT DAT, while the DUIP of 
benztropine was increased around 2-fold by this mutation.  Alanine mutation at the same 
position (T472A) displayed WT-like affinity and DUIP of benztropine.  D384A 
substitution reduced benztropine affinity by 7-fold and DUIP by 5-fold, while the D384N 
mutant did not significantly alter either affinity or DUIP of benztropine.  The I468C 
substitution did not affect the affinity or DUIP of benztropine, while the I468A mutant 
increased benztropine affinity 3-fold (Table 3).  The ratios of DUIP-to-binding affinity 
for the different DAT mutants were also calculated (Table 3).    WT DAT displayed 2-
fold lower DUIP than affinity for benztropine (ratio = 2).  The H476A mutant displayed 
the same Ki and IC50 for benztropine (ratio = 1).  Mutations F542A and Y88A decreased 
the DUIP of benztropine 2-fold compared to the corresponding binding affinity.  The 
T472A substitution behaved the same as WT DAT, while the T472K mutation increased 
DUIP 2-fold versus the binding affinity of benztropine.  DUIP of benztropine was the 
same as binding affinity at mutation D384A, whereas D384N decreased the DUIP of 
benztropine 3-fold relative to the binding affinity.  Mutation at I468A decreased DUIP of 
benztropine by 7-fold relative to binding affinity, while I468C behaved as WT DAT 
(Table 3). 
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Table 3.  Binding affinity and DUIP of benztropine at N2A neuroblastoma cells or 
COS 7 cells transiently expressing DAT constructs. 
 Ki and IC50 values were assessed from experiments incubating transiently 
transfected cells with benztropine in the presence of [3H]-WIN35,428 or [3H]-dopamine 
at room temperature in KRH/AA buffer.  Values represent the mean ± SEM from at least 
three independent experiments, each conducted in duplicate determinations.  Ratios were 
calculated using the IC50 values and Ki values. 
 
DAT 
Construct 
Benztropine 
 Ki / nM Affinity 
change     
(vs. WT) 
IC50 / nM DUIP change 
(vs. WT) 
DUIP/Ki
WT 111 ± 17  210 ± 41  2 
R85D 283 ± 31* ↓ 2.5 ND  ND 
R85D/D475R 1168 ± 172* ↓ 10 ND  ND 
H476A 144 ± 28 – 177 ± 24 – 1 
F542A 88 ± 12 – 242 ± 48 – 3 
Y88A 91 ± 11 – 279 ± 23 – 3 
T472A 131 ± 24 – 219 ± 21 – 2 
T472K 237 ± 74 ↓ 2 123 ± 32* ↑ 2 0.5 
D384A 823 ± 183* ↓ 7 970 ± 99* ↑ 5 1 
D384N 128 ± 14 – 447 ± 88 ↓ 2 3 
I468C 65 ± 6.4 ↑ 2 145 ± 6.4* – 2 
I468A 37 ± 2.3* ↑ 3 265 ± 23 – 7 
* P < 0.05 vs. WT DAT 
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2. Discussion 
Guided by the comparative DAT model, sixteen DAT mutants were made by site-
directed mutagenesis and pharmacologically characterized via [3H]-WIN 35,428 binding 
displacement and [3H]-dopamine uptake inhibition assays.  The effect of disrupting and 
reconstituting the potential TM 1 – TM 10 bridge on DAT expression, inhibitor 
recognition and substrate uptake was addressed because the DAT R85 – D475 salt bridge 
appears to line the floor of the cocaine/TCA binding pocket, and because D475 could 
potentially interact with the protonated N-8 tropane nitrogen atom of cocaine.  The R85D 
and D475R mutants would disallow formation of the bridge; the switch mutant 
R85D/D475R should permit re-establishment of the salt bridge while reversing the side 
chains at these positions.  Unlike the WT DAT, none of the three DAT mutants displayed 
detectable uptake of [3H]-dopamine in the screening assays (Fig. 12).  It is not surprising 
that the DAT switch mutant would be a defective transporter due to the importance 
ascribed to the analogous residues in the LeuT substrate translocation cycle (Yamashita, 
Singh et al. 2005; Zhou, Zhen et al. 2007).  Specific binding of the cocaine analog [3H]-
WIN35,428 was decreased or eliminated by the single R85D or D475R mutations, but 
restored to above WT DAT levels when both positions were simultaneously mutated 
(R85D/D475R) (Fig. 12).  Given the observation that the number of drug-accessible 
double mutant DAT molecules measured by maximal [3H]-WIN 35,428 binding (Bmax) 
was 9-fold higher than R85D DAT but 2-fold lower than WT (Table 1), the 
compensatory net binding increase of the DAT double mutant R85D/D475R relative to 
the single mutants can largely be accounted for by partial recovery of DAT expression.  
The finding that addition of a second mutation reversed the poor expression level due to 
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the first mutation, suggests that an interaction between the TM 1 and TM 10 residues at 
least provides protein infrastructure and stability.  D475R DAT did not display sufficient 
binding for Bmax determination.  It was not determined whether the poor D475R DAT 
binding was due to poor transporter expression, loss of affinity for WIN 35,428, or both.  
The improvement of net binding at the R85D/D475R double mutant was also due to a 9-
fold affinity increase relative to WT DAT.  Clomipramine binding was also assessed 
because the R85 – D475 salt bridge is suggested to be important for TCA binding in the 
DAT model.  R85D displayed a Ki of 2001 ± 201 nM and the switch mutant displayed a 
Ki of 2033 ± 199 nM.  Relative to WT DAT (6946 ± 483 nM), the binding affinity of 
both R85D DAT and R85D/D495R DAT increased 3-fold.  The R85D change was solely 
responsible for this affinity increase; in fact, the affinities of WIN 35,428, cocaine and 
clomipramine did not differ significantly between R85D DAT and the double mutant 
(Tables 1 and 2).  The observation that the pharmacologic profile of clomipramine was 
altered by the mutations in a manner similar to that of cocaine and its analog WIN 35,428 
supports the idea of a common inhibitor binding pocket between these three inhibitors.  
Benztropine diverged from this pattern, with significant affinity decreases at each 
mutant (Table 3).  The pharmacologic findings indicate that the TM 1 R85 residue is 
probably not critical for binding of cocaine or clomipramine; in fact, reversing the side 
chain charge at this position actually increased cocaine affinity.  R85D and D475 side 
chains may repel each other, and thus increase the width of the inhibitor binding pocket.  
The enlarged binding pocket might allow cocaine to access “deeper” regions of the ligand 
cavity and establish additional hydrophobic interactions that explain the affinity increase.  
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The finding that mutagenesis-based disruption of the putative salt bridge did not decrease 
cocaine affinity is consistent with the postulate that cocaine recognizes outward-facing 
MAT conformations (Chen and Justice 1998; Loland, Desai et al. 2008).  As shown in 
Fig. 8, at least three conformational states are suggested to occur during the transport 
process for LeuT: open-to-outside (outward facing), occluded (substrate and ion bound) 
and open-to-inside (inward facing).  Like LeuT, DAT undergoes similar conformational 
conversions during transportation cycle.  The TM 1 – TM 10 salt bridge is part of the 
extracellular gate.  Closing the external gate is the prerequisite for the transporter to 
progress to the next transporter step.  Thus, breaking of the salt bridge via above 
mentioned mutations would trap the transporter in an outward-facing conformation, 
which is preferred by cocaine binding.  Therefore, elimination of a potential TM 1 – TM 
10 salt bridge should not compromise cocaine binding, given that the external gate is 
presumably open in such a conformation.  However, benztropine and cocaine appear to 
recognize different DAT sites or conformations (Reith, Berfield et al. 2001; Newman and 
Kulkarni 2002; Chen, Zhen et al. 2004; Ukairo, Bondi et al. 2005; Loland, Desai et al. 
2008).  In contrast to cocaine, benztropine is postulated to recognize the inward-facing 
DAT conformation (Loland, Desai et al. 2008).  The external gate would be expected to 
be closed for the transporter to convert to the inward-facing conformation, so eliminating 
the TM 1 – TM 10 bridge via the above mutations should impair benztropine binding.  
Nevertheless, the outward-facing cocaine-recognizing DAT conformation is predictably 
less dependent on the external gate TM 1 – TM 10 salt bridge.  Thus, the above 
pharmacologic findings are consistent with previous study results that cocaine and 
benztropine recognize different conformations.  The present study along with the LeuT-
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TCA crystals indicate that binding of cocaine or a TCA drug drives closure of the 
external gate portion in the form of the TM 1 – TM 10 salt bridge, but formation of the 
bridge is not essential for high affinity binding of these drugs. 
 A K92 – D312 salt bridge is also suggested in the DAT model.   Thus, the effect 
of disrupting and reconstituting this potential TM 1 – TM 6 bridge on DAT expression, 
inhibitor recognition and substrate uptake was addressed.  The K92D and D312K mutants 
would disallow formation of the bridge; the double mutant K92D/D312K should permit 
re-establishment of the salt bridge while reversing the side chains at these positions.  The 
K92D mutant displayed detectable but very low [3H]-WIN 35,428 binding and [3H]-
dopamine uptake, while neither the single mutant D312K nor the switch mutant 
K92D/D312K displayed specific [3H]-WIN 35,428 binding or [3H]-dopamine uptake (Fig. 
12).  Given that K92D DAT displayed specific binding and uptake of the radioligand, the 
loss of binding and uptake of the switch mutant might largely be accounted for by the 
single mutant D312K.  D312 may play multiple roles in the many DAT conformations 
involved the substrate translocation cycle, so it is not surprising that the switch mutant 
would be defective in some aspect of transport.  Moreover, D313 (the counterpart of 
D312 in human DAT) was suggested to be involved in cation interactions and control in 
part the ability of Na+ to drive the DAT between inward-and outward-facing 
conformations (Surratt, Ukairo et al. 2005).  Thus, the above results are consistent with 
previous findings.  However, the presence of the K92-D312 salt bridge cannot be 
determined from the current data.  It is not determined whether the poor DAT binding 
(D312K and K92D/D312K) was due to poor transporter expression, loss of affinity for 
WIN 35,428, or both.  The surface expression of these mutants could be further 
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investigated via biotinylation assay.  Additionally, different radiolabeled ligands such as 
[3H]-mazindol and [3H]-BTCP can be employed to determine whether the poor DAT 
binding was due to loss of affinity for WIN 35,428. 
H476, unique to the DAT, establishes H-bond and hydrophobic interactions with 
cocaine but not benztropine in the DAT model. Alanine replacement of H476 removes 
any significant partial positive charge, H-bonding, side chain length and any π electron 
contributions.  Relative to WT DAT, a slight but not significant decrease was observed 
with the net binding of H476A.  The slightly reduced net binding of the H476A mutant 
was probably due to the loss of DAT expression.  Measured by maximal [3H]-WIN 
35,428 binding, the number of drug-accessible protein molecules was 3-fold lower than 
WT DAT.  The loss of surface expression could be due to the decreased protein synthesis 
or the decreased translocation of protein to the cell membrane.  Given that Golgi 
apparatus processes and packages all proteins after their synthesis, the amount of the 
target protein in the Golgi apparatus could be evaluated to determine what causes the loss 
of the protein surface expression.  The H476A mutant displayed WT-like affinity for 
WIN35,428, cocaine and benztropine (Tables 1, 2 and 3).  The DUIPs of cocaine and 
benztropine were not affected by this mutation.  The ratio of DUIP to binding affinity for 
the mutant changed from 2 to 1, suggesting a slight difference in the behavior due to the 
alanine replacement.  H476 is suggested by the DAT model to differentiate cocaine and 
benztropine binding.  Alanine substitution should influence cocaine binding without 
changing the benztropine binding profile.  However, the pharmacologic findings indicate 
that the TM 10 H476 residue is probably not critical for binding of either cocaine or 
benztropine.  Given that the dopamine uptake level was not changed, H476 is probably 
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not important to the DAT infrastructure.  F542 and Y88 appear to form π-π stacking with 
aromatic rings of both cocaine and benztropine aromatic groups in the DAT model.  Y88 
can also H-bond with the C-2 ester of cocaine.  Given that alanine substitution will 
remove any aromaticity and H-bonding contributions, the F542A and Y88A mutation are 
supposed to eliminate the protein-inhibitor interaction and thus affect the binding of 
cocaine and benztropine.  Binding assays demonstrated that F542A and Y88A did not 
alter the affinities for WIN, cocaine or benztropine (Tables 1, 2 and 3).  Bmax values 
measured at these two mutants were also similar to WT DAT (Table 1).  The WT-like 
binding observed at F542A DAT and Y88A DAT (Fig. 12) is consistent with the 
unaltered affinity and Bmax values.  The DUIP of cocaine decreased 3 to 4 fold by alanine 
replacement at either of these two residues, which led to DUIP-to-binding affinity ratios 
dropping 3 fold, suggesting that F542 and Y88 may play some role for cocaine’s effect 
on the DAT.  The DUIPs of benztropine at these two mutants were similar to WT DAT.  
The pharmacologic findings indicate that the TM 1 Y88 and TM 10 F542 amino acid 
residues might not interact with WIN35,428 or benztropine, or form their binding pockets.  
In addition, these two residues are probably not critical for DAT infrastructure.G425 (TM 
8) is conserved in MATs (DAT, SERT and NET).  The analogous position in LeuT is 
occupied by I359, which is important for the binding site of LeuT.   The aliphatic side 
chain of leucine is cradled with a hydrophobic pocket created by side chain atoms of 
V104, Y108, F253, S256, F259, S355 and I359.  The complementarity of the van der 
Waals surface formed by the side chain of these residues to the side chain of L-leucine is 
consistent with the specificity of LeuTAa for its substrate.  These amino acid residues 
shape the leucine binding site and determine the substrate specificity in the eukaryotic 
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homologues.  For example, I359 is replaced with a smaller size amino acid glycine in 
MATs to accommodate the larger substrate molecules.  (Yamashita, Singh et al. 2005).   
Isoleucine substitution for glycine will increase the side chain length and the potential for 
hydrophobic interactions, but also the steric hindrance; moreover, the replacement may 
alter the DAT binding site to some extent similar as that of LeuT.  G425I displayed 
neither specific uptake of [3H]-dopamine nor [3H]-WIN 35,428 binding (Fig. 12).  Given 
the fact that this residue is important for LeuT substrate translocation, it is not surprising 
that this mutant displayed as a defective transporter.  It was not determined whether the 
poor G425I DAT binding was due to poor transporter expression, loss of affinity for WIN 
35,428, or both.  T472 directly contacts cocaine in the “gate closed” poses, and also in the 
“gate open” pose for benztropine in the DAT model.  Alanine replacement will shorten 
the side chain and eliminate the potential for H-bonding but preserve the α-helical nature 
of the transmembrane domain.  Lysine substitution will lengthen the side chain and 
preserve the H-bonding potential.   The WIN 35,428 net binding of T472A and T472K is 
similar to WT DAT (Fig. 12).  The number of drug-accessible DAT molecules as well as 
affinities of WIN 35,428, cocaine and benztropine did not differ from those of WT DAT 
(Tables 1 - 3), supporting the observation of WT-like net binding at these two mutations.  
The DUIP of cocaine was decreased around 3-fold by T472A and T472K, leading to the 
increase in DUIP/Ki ratio to 3.  The DUIP of benztropine for T472A was similar to WT 
DAT, while 2-fold improvement resulted from the T472K mutation.  With respect to this 
ratio, T472A substitution behaved the same as WT DAT, while the T472K mutation 
reversed the ratio from 2:1 to 1:2.  The T472 (TM 10) residue is probably not important 
for binding of WIN 35,428 and benztropine, from the observation of WT-like binding 
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affinities for these inhibitors.  The decreased DUIP of cocaine and benztropine suggests 
that this residue might be involved in the substrate translocation cycle.  The change in the 
DUIP:binding affinity ratio for cocaine and dopamine indicates mutation-induced 
differences.  Intriguingly, lysine replacement affected cocaine and benztropine DUIP 
differently.  The three-fold loss of cocaine DUIP versus 2-fold gain of benztropine DUIP 
suggests that the T472K mutant differentiates cocaine and benztropine.  In another words, 
the increase of the side chain length via lysine substitution decreased cocaine’s DUIP, 
while the DUIP of benztropine improved by this substitution.  Additionally, this finding 
is consistent with the postulate that cocaine and benztropine recognize different DAT 
sites or conformations (Reith, Berfield et al. 2001; Newman and Kulkarni 2002; Chen, 
Zhen et al. 2004; Ukairo, Bondi et al. 2005; Loland, Desai et al. 2008).  Cocaine appears 
to recognize outward-facing MAT conformations, while benztropine is postulated to 
recognize the inward-facing DAT conformation (Chen and Justice 1998; Loland, Desai et 
al. 2008).   T472K mutant might play some role to trap the transporter in the inward-
facing conformation, which is recognized by benztropine.D384 (TM 8) contributes to 
cocaine and benztropine binding in the “gate closed” state.  Alanine substitution will 
remove charge and H-bonding potential, while asparagine replacement eliminates the 
negative charge of aspartic acid but retains the side chain length and H-bond potential.  A 
mild decrease of the WIN 35,428 net binding was found with D384A DAT (Fig. 12), 
which is largely accounted for by the loss of WIN binding affinity and lower Bmax value 
(Table 1).  D384N displayed WT-like WIN affinity and Bmax (Table 1).  The D384A 
substitution decreased cocaine affinity 3-fold and DUIP 6-fold, while the D384N mutant 
only impaired cocaine affinity by 3-fold (Table 2).  Thus, the 3:1 DUIP:binding affinity 
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ratio for D384A versus 1:2 for D384N suggests different DAT behavior as a function of 
the substitution.  Moreover, alanine substitution decreased benztropine affinity by 7-fold 
and DUIP by 5-fold, while the asparagine mutant did not alter either affinity or DUIP of 
benztropine (Table 3).  The ratio of DUIP/Ki for benztropine was 1 for D384A and 3 for 
D384N, relative to 2 for WT DAT.  D384A also displayed WT-like clomipramine 
affinity (Appendix 1, Fig 22).  The pharmacological findings suggest that D384 is 
probably important for cocaine and benztropine binding to DAT, while the residue might 
not be crucial for DAT infrastructure given that D384N did not affect the DUIP of either 
cocaine or benztropine.  Given that the clomipramine affinity was not altered by alanine 
mutation, D384 might not be involved in the clomipramine binding (neither interact with 
clomipramine nor form its binding pocket).  WIN binding was affected by alanine but not 
asparagine substitution, which is different from a previous report that D384N hDAT 
sustained a 4 to 5 fold loss of WIN affinity (Loland, Norregaard et al. 1999).  Asparagine 
retained the side chain length and H-bonding potential of aspartic acid without bearing 
the negative charge, indicating that the negative charge itself may be not critical for WIN 
binding.  H-bonding and side chain length might be important for WIN binding, based on 
the difference between N and A (compared to asparagine, alanine decreases the side 
chain length and eliminates H-bond potential).   It was proposed that WIN binding would 
be same as cocaine binding at the mutants because WIN is the analog of cocaine.  
However, the D384N mutation only affected cocaine affinity, implying that binding sites 
of cocaine and WIN might be slightly different.  Cocaine affinity was altered similarly at 
D384A and D384N mutations, indicating that the negative charge of D384 might be 
important for cocaine binding (D384 may potentially interact with the protonated N-8 
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tropane nitrogen atom of cocaine).  Taking the above findings together, the orientation of 
WIN in the binding site might be different from cocaine in that the protonated nitrogen 
atom of WIN is not within the reach of D384.  Therefore, WIN might interact with the 
DAT protein through H-bonding and hydrophobic interactions, while cocaine interacts 
with the DAT mainly through ionic pairing.  Benztropine binding and DUIP were 
affected by the D384A but not D384N mutation, indicating that H-bonding and 
hydrophobic interactions might be important for the recognition of benztropine. 
The TM 10 I468 residue contributes to binding sites for cocaine and benztropine 
in the “gate closed” state.  Alanine substitution will shorten the side chain length and 
decrease side chain bulk, while replacement with cysteine will shorten the side chain 
length and add H-bonding potential.  The I468C mutation markedly decreased net 
binding (Fig. 12), largely due to the loss of DAT expression (30-fold decrease in Bmax).  
WIN affinity was same as WT DAT (Table 1).  I468A displayed WT-like affinity to WIN 
and a 2-fold loss of binding sites (Table 1).  Cysteine substitution at I468 did not alter 
either the affinity or DUIP of cocaine, while alanine displacement at this position slightly 
increased cocaine affinity 1.5-fold (Table 2). H-bonding might not form with I468C and 
cocaine, given the fact that cocaine affinity was not changed by this substitution.  Based 
on the observation that I468A did not appreciably change cocaine affinity, the side chain 
size and length is probably not important for cocaine binding.  I468C substitution did not 
affect DUIP or affinity of benztropine, while the I468A mutant increased benztropine 
affinity 3-fold (Table 3).  The increase of benztropine affinity is probably due to the 
decreased size of the side chain.  The pharmacological findings indicate that the size of 
side chain is probably critical for binding of benztropine.  The less bulky alanine side 
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chain seems to allow benztropine to access “deeper” regions of the ligand cavity and 
establish additional interactions that explain the affinity increase. 
By and large, pharmacological feedback from the mutagenesis study confirmed 
some of the suggestion from the DAT model, which is encouraging, that the comparative 
DAT model is valid to some extent and could be further used for ligand docking and 
virtual screening.  Some mutants displayed a WT-like profile, suggesting that the DAT 
model needs to be refined at these positions.  However, this is still valuable information 
in elucidating the binding sites and refining the DAT model.  With the reliable 
information of ligand binding sites, novel compounds that bind to DAT could be 
designed and/or discovered as antiaddiction medications and therapies to treat other DA-
mediated disorders such as depression, Parkinson’s disease, anxiety, narcolepsy and 
chronic pain.  Overall, site-directed mutagenesis and pharmacological assays could 
illuminate the role of different amino acid residue in DAT, and help to validate and refine 
the DAT model for elucidating the binding sites of different ligands, finally aid the 
process for novel drug design and discover. 
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B. Pharmacological characterization of analogs of classic non-tropane DAT 
inhibitors 
1. Results 
The purpose of present pharmacological study of non-tropane-based DAT ligands 
is to find high affinity candidate compounds that could be further radiolabeled and used 
in the subsequent crosslinking and proteolysis assays to identify the binding pocket of 
DAT. 
DAT binding affinity and dopamine uptake inhibition potency (DUIP) for various 
non-tropane analogs were assessed via [3H]-WIN35,428 displacement and [3H]-dopamine 
uptake inhibition assays, respectively, in N2A neuroblastoma cells stably expressing 
wild-type hDAT.  The analogs tested were based on the non-tropane drugs (±)-
pyrovalerone, (±)-bupropion, modafinil and (±)-methylphenidate. 
(±)-SADU 2-110B, a pyrovalerone analog (benzyl group substitution for the 
propyl group), decreased DAT binding affinity 60-fold relative to the 8 nM Ki value for 
pyrovalerone (Lapinsky, Aggarwal et al. 2009); the DUIP was not altered by the 
5modification (Fig. 13, Table 4).  Increased steric hindrance by the addition of the phenyl 
ring might be the reason for the significant loss of DAT binding affinity.  To determine 
whether the steric hindrance is important for binding affinity, larger alkyl groups, such as 
ethyl, propyl and butyl could be introduced to this position.  The bupropion analog (±)-
SADU 2-174 (3-iodo-4-azido substitution) decreased DAT binding affinity 4-fold 
relative to bupropion (Ki = 441 nM; (Lapinsky, Aggarwal et al. 2009).  The addition of 
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the azido group might account for the loss of DAT binding affinity.  The binding affinity 
of (±)-SADU 3-3 (hydrochloride salt of SADU 2-174) decreased 10-fold (Ki around 4.5 
µM derived from two experiments; Fig. 13, Table 4).  Modafinil, an analeptic drug, is 
used for the treatment of narcolepsy.  It binds to DAT with affinity around 1 µM and 
DUIP around 8 µM (Appendix 2, Fig 23).  Modafinil can partially displace cocaine from 
DAT at the concentration of 10 µM (Appendix 2, Fig 24).  DJLDU 2-95, an analog of 
modafinil, increased binding affinity and DUIP by 10-fold and 34-fold, respectively (Fig. 
13, Table 4).  The substituted piperazine might help the drug incorporate with DAT 
protein better than the original amide group and thus lead to the augmentation of binding 
affinity and DUIP. 
 
Figure 13.  Chemical structures of non-tropane based compounds and their analogs. 
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Table 4.  DAT binding affinities and dopamine uptake inhibition potencies (DUIPs) 
of non-tropane based DAT ligands at hDAT N2A neuroblastoma cells.   
Ki and IC50 values were derived from experiments incubating WT hDAT N2A 
cells with nonradioactive DAT ligands in the presence of [3H]-WIN35,428 or [3H]-
dopamine at room temperature in KRH/AA buffer. Values represent the mean ± SEM 
from at least three independent experiments, each conducted in duplicate determinations.   
 
Compound 
 
DAT Binding 
(Ki/nM) 
DUIP 
(IC50/nM) 
(±) SADU 2-110B  480 ± 99 1366 ± 153 
(±) SADU 2-174  1775 ± 381 - 
(±) SADU 3-3         
Hydrochloride salt of (±) SADU 2-174 
  
5087, 4023 - 
Modafinil 1548 ± 357 8144 ± 927 
DJLDU 2-95  161 ± 44a 236 ± 54b 
a P<0.05 vs. Ki of modafinil; b P<0.05 vs. IC50 of modafinil  
Racemic threo-methylphenidate ((±)-1) and its analogs (2-18) were assessed via 
[3H]-WIN35,428 displacement and [3H]-dopamine uptake inhibition assays, respectively, 
in N2A neuroblastoma cells stably expressing wild-type hDAT.  DAT binding affinity 
and DUIP were not altered by hydroxymethyl substitution at the R2 position and benzyl 
substitution at the R3 position ((±)-2).  Further modification at R3 with a 3-iodo-4-azido 
benzyl group ((±)-3) failed to display a consistent DAT binding affinity due to the poor 
solubility of this compound (Fig. 14, Table 5).  Methyl substitution at R3 ((±)-4) 
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decreased binding affinity 3-fold and DUIP 1.5-fold, suggesting that the methyl group is 
mildly tolerated at this position (Fig. 14, Table 5).  DAT affinity was improved 
approximately 5-fold upon substituting the 3-position of methylphenidate’s aromatic ring 
with iodine ((±)-5), further supporting the observation that halogens are tolerated at this 
position (Deutsch, Shi et al. 1996) and suggesting an anchoring position for 125I as a 
radiotracer tag.  The DUIP of 3-iodo-methylphenidate ((±)-5) was also improved by 10-
fold (Fig. 14, Table 5).  The DAT binding affinity of 4-iodo-methylphenidate (iodine 
substitution at the para position of methylphenidate’s aromatic ring) ((±)-12) was 
approximately 2-fold higher than methylphenidate, while the DUIP of this compound 
increased 14-fold (Fig. 14, Table 5).  DAT binding affinity and DUIP were diminished 
(46-fold and 4-fold, respectively) by 4-iodo-phenyl substitution at R3 ((±)-6).  Affinity 
was even worse (130-fold loss vs. 1) with compound (±)-7 bearing a further modification 
of 3-iodo-4-azido-benzyl group at R3, suggesting that the presence of a halogen and an 
azo group on the R3 aromatic ring might not be tolerated.  Compound (±)-8, a modified 
version of (±)-5 that adds a 4-azido-benzyl substitution at the R3 position, decreased 
binding affinity by 26-fold as well as 12-fold for DUIP (Fig. 14, Table 5).  Affinity was 
5-fold lower than methylphenidate by propenyl substitution at R2 ((±)-9), whereas DUIP 
was decreased 2-fold by this modification.  Ethyne substitution at the 3-position of 
methylphenidate’s aromatic ring ((±)-10) improved binding affinity 7-fold and DUIP 40- 
fold.  DAT binding affinity was reduced 23-fold by the addition of 4-azido-phenyl group 
to the methyl ester group at position R2 ((±)-11) based on the 3-iodo-methylphenidate 
structure.   The 4-azido-benzyl substitution at the R3 position of 4-iodo-methylphenidate 
((±)-13) decreased affinity 14-fold, whereas DUIP was decreased 18-fold.  Compound 
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(±)-14, bearing a 3-azido-benzyl group at the R3 position of 3-iodo-methylphenidate, 
impaired binding affinity 82-fold as well as decreasing DUIP by 30-fold.  Binding 
affinity was 21-fold lower with 2-azido-benzyl replacement at the R3 position of 4-iodo-
methylphenidate ((±)-15), while DUIP was also decreased 8-fold.  The 3-iodo-4-azido-
benzyl substitution at R3 ((±)-16) impaired binding affinity and DUIP by 76-fold and 49-
fold, respectively.  The 2-azido-benzyl substitution at R3 of 3-iodo-methylphenidate ((±)-
17) decreased affinity 44-fold, whereas DUIP was diminished 17-fold.  A 110-fold 
decrease of binding affinity was observed upon substituting the 4-position of 
methylphenidate’s aromatic ring with iodine and an N-3-azido-benzyl substitution ((±)-
18), while 49-fold loss of DUIP was observed (Fig. 14, Table 5). 
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Compound R1 R2 R3 
1 Ph COOCH3 H 
2 Ph CH2OH CH2Ph 
3 Ph CH2OH CH2-(3’-I, 4’-N3)-Ph 
4 Ph COOCH3 CH3 
5 3’-I-Ph COOCH3 H 
6 Ph COOCH3 4’-I-Ph 
7 Ph COOCH3 CH2-(3’-I, 4’-N3)-Ph 
8 3’-I-Ph COOCH3 CH2-(4’-N3)-Ph 
9 Ph COOCH2CH=CH2 H 
10 3’-C≡CH-Ph COOCH3 H 
11 3’-I-Ph COOCH2-(4’-N3)-Ph H 
12 4’-I-Ph COOCH3 H 
13 4’-I-Ph COOCH3 CH2-(4’-N3)-Ph 
14 3’-I-Ph COOCH3 CH2-(3’-N3)-Ph 
15 4’-I-Ph COOCH3 CH2-(2’-N3)-Ph 
16 Ph COOCH3 CH2-(3’-I, 4’-N3)-Ph 
17 3’-I-Ph COOCH3 CH2-(2’-N3)-Ph 
18 4’-I-Ph COOCH3 CH2-(3’-N3)-Ph 
 Figure 14.  Chemical structures of methylphenidate (1) and its analogs (2-18). 
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Table 5.  DAT binding affinities and dopamine uptake inhibition potencies of 
methylphenidate-based DAT ligands at hDAT N2A neuroblastoma cells.   
Ki and IC50 values were derived from experiments incubating hDAT N2A cells 
with nonradioactive DAT ligands in the presence of [3H]-WIN35,428 or [3H]-dopamine 
at room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least 
three independent experiments, each conducted in duplicate determinations.   
Compound 
Binding to DAT 
(Ki/nM) 
DUIP 
(IC50/nM) 
1(Methylphenidate) 25 ± 1* 156 ± 58* 
2 28 ± 7 107 ± 22 
3 177.3, 878.8, 860.8, 979, 
1108 (solubility problem) - 
4 70 ± 8a 238 ± 14c 
5 4.5 ± 1a 14 ± 5b 
6 1147 ± 241a 663 ± 40b,c 
7 3243 ± 804 - 
8 658 ± 70a 1828 ± 261b,c 
9 123 ± 7.9a 358 ± 11b,c 
10 3.5 ± 0.1a 3.9 ± 1.1b 
11 586 ± 61a - 
12 14 ± 3a,* 11 ± 2b 
13 363 ± 28a,* 2764 ± 196b,c 
14 2056 ± 73a 4627 ± 238b,c 
15 517 ± 65a 1232 ± 70b,c 
16 1911 ± 271a 7599 ± 106b,c 
17 1112 ± 163a 2696 ± 178b,c 
18 2754 ± 169a 7966 ± 348b,c 
 aP<0.05 vs. Ki of (+)-1, threo-methylphenidate; bP<0.05 vs. IC50 of (+)-1, threo-
methylphenidate; cP<0.05 vs. its corresponding Ki.* Experiments done by Yurong Huang. 
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2. Discussion 
Analogs of non-tropane based drugs (pyrovalerone, bupropion, modafinil and 
methylphenidate) were tested in this study to help to find the potential photoaffinity 
ligands used for crosslinking and proteolysis studies.  A dramatic loss (60-fold) of DAT 
binding affinity was found for the pyrovalerone analog, suggesting that substituting the 
propyl group of pyrovalerone with a benzyl group appears to increase steric hindrance 
and thus inhibit the interaction between the drug and DAT protein.   Addition of an azido 
group to bupropion’s aromatic ring appears to modestly impair the drug-DAT interaction 
(4-fold affinity decrease).  In addition, iodine replacement of chlorine might also affect 
drug recognition by the DAT protein.  DJLDU 2-95, an analog of modafinil, increased 
binding affinity and DUIP by 10-fold and 34-fold, respectively (Fig. 13, Table 4).  Two 
cation centers generated by the addition of piperazine may form an ionic bond with the 
DAT protein.  In addition, the side chain length, hydrophobic and π-stacking potential, 
and flexibility are significantly increased by the substituted piperazine of the modafinil 
analog.  Those modifications appear to improve the incorporation of the drug in the DAT 
protein; e.g., the more flexible side chain may allow the drug to dock deeper into the 
primary substrate/inhibitor pocket).  The low nanomolar affinity suggests that DJLDU 2-
95 could be further modified (addition of azido and iodo groups) to develop a potential 
photoaffinity probe.   Modafinil itself was tested with some of the DAT mutants 
(Appendix 2, Table 9 and Fig 25).  In contrast to WT DAT, the binding affinity of R85D 
decreased 5-fold, suggesting that R85 might be involved in the modafinil binding pocket 
(either interacting with modafinil or forming the binding pocket).  To determine whether 
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the binding site of analog DJLDU 2-95 is different from modafinil as proposed, DJLDU 
2-95 could be further investigated with mutated DAT proteins.   
A series of methylphenidate analogs (2-18) were assessed in parallel to racemic 
threo-methylphenidate ((±)-1) via [3H]-WIN35,428 displacement and [3H]-dopamine 
uptake assays.  Remarkable improvement of binding affinity (7-fold) and DUIP (40-fold) 
was observed for (±)-10, bearing an ethyne substitution at the 3-position of 
methylphenidate’s aromatic ring, suggesting that the modification is tolerated at this 
position.  Iodine substitution ((±)-5) at the same position was also observed to increased 
binding affinity and DUIP by 5-fold and 10-fold, respectively, supporting the observation 
that halogens are tolerated at this position (Deutsch, Shi et al. 1996; Misra, Shi et al. 
2010).  Iodine substitution at the 4-position of methylphenidate’s aromatic ring increased 
binding affinity 2-fold and DUIP 14-fold as well.  A previous study with the same 
substitution displayed a 6-fold affinity increase using [3H]-WIN35,428 displacement 
assay (Misra, Shi et al. 2010).   Several analogs were designed and synthesized based on 
3-iodo-methylphenidate or 4-iodomethylphenidate.  The 4-azido-phenyl substitution at R2 
of 3-iodo-methylphenidate displayed affinity in the nanomolar range (Ki = 586 ± 61 nM).  
Substituting the piperidine nitrogen of these iodo-methylphenidates with a N-benzyl 
group bearing an aromatic azo group resulted in a significant decrease in DAT binding 
affinity (~14-fold to 110-fold lower binding affinity than methylphenidate) as well as 
DUIP (~ 8-fold to 49-fold lower than that of methylphenidate). N-(p-azido-benzyl)-4-
iodomethylphenidate ((+)-13) displayed the highest DAT affinity (Ki = 363 ± 28 nM) out 
of the series of hybrid compounds.  DAT binding affinity displayed differently with 
respect to the position of the azide group on the N-benzyl aromatic ring.  Substitution of 
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the azide at the para position decreased binding affinity by 14-fold (3-iodo-
methylphenidate) and 26-fold (4-iodo-methylphenidate), while the ortho position 
substitution resulted in a greater loss of affinity (21-fold for 3-iodo-methylphenidate and 
44-fold for 4-iodo-methylphenidate).  However, substitution of the azide at the meta 
position resulted in a much greater decrease in DAT binding affinity (110 and 82-fold 
lower binding affinity than methylphenidate).  Thus, these designed azido-N-benzyl-
iodo-methylphenidates behaved unlike previously reported methylphenidates in which N-
benzyl substitution either increased or retained DAT affinity (Misra, Shi et al. 2010).  
There was no obvious advantage in terms of DAT binding affinity associated with the 
position of the iodine in these hybrid analogs (average Ki: 3-iodo compounds = 1280 nM; 
4-iodo compounds = 1210 nM).   
With respect to identifying candidate probes for a photoaffinity labeling study, 
ideal compounds are those that retain similar bioactivity as the parent compound.  
However, compounds with as much as 1000-fold lower activity can still be useful 
(Dorman and Prestwich 2000).  Therefore, compound (±)-13 (Ki = 363 ± 28 nM), 
displaying the highest DAT affinity out of the series of methylphenidate analogs, was 
further developed into a potential DAT photoaffinity probe.  The radiolabeled 125I-(±)-13 
was synthesized by the laboratory of Dr. John Lever (Univ. Missouri).  The 
radioiodinated version was assessed via photoaffinity labeling experiments (Dr. Roxanne 
Vaughan’s group, Univ. North Dakota).  The radiolabeled analog was successfully 
incorporated into the DAT, and co-incubation of 125I-(±)-13 with nonradioactive D-(+)-
methylphenidate or (–)-2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane (β-CFT, WIN-
35,428, a cocaine analog) blocked DAT labeling (Fig. 15).  The successful incorporation 
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of the radiolabeled analog indicates that the analog is binding to the DAT protein. In 
addition, the displacement binding implies that the radiolabeled analog is binding to the 
same binding pocket as cocaine and methylphenidate.  In aim 1, the mutagenesis studies 
were based on the predicted binding pocket of cocaine and benztropine.  The results 
suggest that the DAT region interacting with the analog is same as the binding pocket 
predicted from aim 1.  Therefore, aim 2 partially supports aim 1.  To determine which 
amino acid is involved in the binding of this photoaffinity probe, the covalent interaction 
between 125I-(±)-13 and DAT protein will be further explored by DAT proteolysis and 
identification of the drug-bound DAT fragment via western blotting.  Docking of 
compound (±)-13 with the DAT model will then indicate the most likely residue(s) for 
the point of crosslink, and these targets will be addressed via site-directed mutagenesis.   
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Figure 15.  Photoaffinity labeling of DAT with [125I]-(+)-13.   
Rat striatal membranes were photoaffinity labeled with 30 nM [125I]-(+)-13 in the 
absence or presence of 10 µM or 100 µM β-CFT or D-MPH.  Membranes were 
solubilized and DATs were immunoprecipitated followed by analysis by SDS-PAGE and 
autoradiography.  The relevant portion of a representative autoradiograph is pictured 
followed by a histogram that quantitates relative band intensities.  Mean ± S.E. of three 
independent experiments is shown; ***, p < 0.001 vs. control. Experiments conducted by 
Dr. Roxanne Vaughan’s group. 
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C. Pharmacological characterization of novel DAT ligands identified through in 
silico screening using the DAT model 
1. Results 
Ten virtual screening (VS) “hit” compounds (coded MI-11 through MI-20) were 
selected and purchased based on their optimal score, predicted pKi values, visual binding 
site fitting, availability and price (Fig. 16).  Initially, 10 µM of each VS “hit” compound 
was assessed via [3H]-WIN 35,428 displacement and [3H]-dopamine uptake inhibition 
assays in N2A neuroblastoma cells stably expressing wild type (WT) hDAT.  The [3H]-
WIN 35,428 binding displacement assays demonstrated that MI-15, MI-17 and MI-20 
were able to block [3H]-WIN 35,428 binding in a statistically significant fashion.  In this 
binding screen, MI-17 inhibition approached the potency of the positive control inhibitor 
mazindol, which possesses low nanomolar DAT affinity.  The [3H]-dopamine uptake 
inhibition screening assay indicated that MI-15, MI-17 and MI-20 appreciably inhibited 
dopamine uptake (Fig. 17).  With hDAT N2A cells, MI-15 displayed a DAT affinity of 
801 nM as measured by WIN 35,428 displacement and a DUIP of 1876 nM.  MI-17 
displayed 1298 nM for DAT affinity and 3774 nM for DUIP.  MI-20 displayed a DAT 
affinity and DUIP of 1351 nM and 4133 nM, respectively (Fig. 18, Table 6).   
 
92 
 
N
N
HO
HO
NHO
N
N
NN
HO
N N
N
F
NN
NH
O
Cl
HO
OH
OH
N
N
N
N
N
HO
N
NHO
N
N
S
O
N
N
O
Cl
N
HO
HO
N OH
O
Cl
NO
NH2
N
N
NHO
Cl
CF3
N
N
N
HO
N
O
S
HO N
N
N
S
OH
N
OH
CH3HO
HCl
MI-11 MI-12 MI-13
MI-14 MI-15
MI-16
MI-17
MI-18
MI-19
MI-20 MI-4  
Figure 16. Chemical structures of virtual screening “hit” compounds employed 
in [3H]-WIN35,428 displacement and [3H]-dopamine uptake inhibition assays. 
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Figure 17.   Initial DAT binding affinity and dopamine uptake inhibition screening 
for MI-11 to MI-20 at N2A neuroblastoma cells stably expressing WT hDAT. 
 DAT binding affinities were assessed via [3H]-WIN35,428 displacement when 
MI-11 to MI-20 (10 µM) were co-incubated (upper panel).  [3H]-dopamine uptake 
inhibition was assessed by pre-incubation with MI-11 to MI-20 (10 µM) (lower panel). 
The data represent an average of at least 3 separate experiments. 
94 
 
 
Figure 18.   MI-15, MI-17 and MI-20 DAT binding affinity and dopamine uptake 
inhibition potency in N2A cells.  
Inhibition of [3H]-WIN35,428 binding (left panels) and inhibition of [3H]-
dopamine uptake (right panels) at N2A neuroblastoma cells stably expressing WT hDAT 
(n = 3 for each assay).   
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Table 6.  DAT binding affinities and dopamine uptake inhibition potencies of MI 
hits at hDAT N2A neuroblastoma cells.   
Ki and IC50 values were derived from experiments incubating hDAT N2A cells 
with nonradioactive DAT ligands in the presence of [3H]-WIN35,428 or [3H]-dopamine 
at room temperature in KRH/AA buffer. Values represent the mean ± SEM from three 
independent experiments, each conducted in duplicate determinations. 
 
Compound 
Binding to DAT 
(Ki/nM) 
DUIP 
(IC50/nM) 
MI-15 801 ± 91 1876 ± 480 
MI-17 1298 ± 36 3774 ± 407 
MI-20 1351 ± 163 4133 ± 560 
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Several drugs are known to exert their effects by modulating more than one 
neurotransmitters in the brain, such as cocaine and amphetamine.  Cocaine can bind to all 
three monoamine transporters (DAT, SERT and NET) and inhibit the reuptake of the 
corresponding neurotransmitters (dopamine, serotonin and norepinephrine).  Additionally, 
SERT has been considered as a key molecular target for clinically effective 
antidepressants including the tricyclic antidepressants (TCAs), the serotonin and 
norepinephrine reuptake inhibitors (SNRIs) and the selective serotonin reuptake 
inhibitors (SSRIs) (Henry, Defelice et al. 2006).  Therefore, it is of interest to know 
whether those VS “hit” compounds have any effect on other monoamine transporters.  To 
investigate VS “hit” compound binding and substrate uptake inhibition at the human 
serotonin transporter (hSERT), human embryonic kidney (HEK) cells stably transfected 
with SERT cDNAs were employed.  The cocaine analog [125I]-RTI-55 served as the 
binding radioligand, a compound similar to WIN 35,428 in DAT affinity and identical to 
WIN 35,428 except for a para- iodine-for-fluorine substitution on the C-3 phenyl ring.  
Substrate uptake was monitored with [3H]-serotonin.  The screening tests indicated that 
only MI-17 was able to block [125I]-RTI-55 binding and inhibit [3H]-serotonin uptake.  
MI-17 inhibition approached the potency of the positive control inhibitor paroxetine, 
which possesses low nM SERT affinity (Fig. 19).  Interestingly, MI-17 affinity at hSERT 
was 4.5-fold higher than at hDAT, and serotonin uptake inhibition potency (SUIP) was 
similar to that at hDAT (Table 7).  MI-17 was then employed as the lead compound to 
develop compounds with better selectivity to SERT, which could be further developed as 
new SSRIs.  Based on the structure of MI-17, an analog modified predicted to be 
favorable for hSERT binding was synthesized by the Lapinsky lab (DJLDU 3-79) and 
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was tested at hDAT and hSERT.  As expected, DAT binding affinity was not appreciably 
altered (1.6 fold lower) compared to MI-17, while DUIP was not altered by the 
modification.   However, a 13-fold increase in SERT binding affinity was observed with 
the MI-17 analog DJLDU 3-79 (Table 7).  Thus, the modification of MI-17 succeeded in 
improving binding affinity to hSERT without change DAT binding affinity.  In other 
words, SERT/DAT selectivity was improved by this modification, as intended. 
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Figure 19.   Initial SERT binding affinity and serotonin uptake inhibition screening 
for MI-11 to MI-20 at HEK cells stably expressing WT hSERT. 
SERT binding affinities were assessed via [125I]-RTI-55 displacement when MI-
11 to MI-20 (10 µM) were co-incubated (upper panel).  [3H]-serotonin uptake inhibition 
was assessed by pre-incubation with MI-11 to MI-20 (10 µM) (lower panel). The data 
represent an average of at least 3 separate experiments. 
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Table 7.  Binding and substrate uptake inhibition of MI-17 and its analog (DJLDU 
3-79) at hDAT-N2A and HEK-hSERT cells.  
Ki and IC50 values were derived from experiments incubating cells with MI-17 or 
MI-17 analog in the presence of radioligand in N2A neuroblastoma cells stably 
expressing WT hDAT ([3H]-WIN35,428 or [3H]-dopamine) or HEK cells stably 
expressing WT hSERT ([125I]-RTI-55 or [3H]-serotonin). Values represent the mean ± 
SEM from three independent experiments, each conducted in duplicate determinations. 
  
 MI-17 
HO
N OH
O
Cl
 
DJLDU 3-79 
 
DAT binding (Ki/nM) 
 
1298 ± 36 2129 ± 177 
DUIP (IC50/nM) 
 
3774 ± 407 3436 ± 245 
SERT binding (Ki/nM) 
 
284 ± 66 22 ± 13a 
SUIP (IC50/nM) 
 
1167 ± 26 _ 
a   Experiments conducted by Dr. Tammy Nolan.   
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In addition to MI-11 to MI-20, another series of VS “hit” compounds (MI-1 to 
MI-10) were tested previously.  MI-4 (Fig. 16), displaying the highest DAT affinity (6 
µM), was identified out of this series of VS hit.  Moreover, MI-4 displayed a DUIP of 28 
µM. Given that the DUIP of MI-4 was so weak as to be negligible, the possibility that 
MI-4 could reduce cocaine DUIP and thus antagonize the actions of cocaine was 
addressed.  Cocaine inhibition of [3H]-dopamine uptake was assessed using the hDAT 
N2A cell line, in the absence and presence of 10 µM MI-4.  The DUIP IC50 value of 
cocaine alone (291 ± 56 nM) was increased approximately 3-fold (845 ± 118 nM) in the 
presence of MI-4 (Fig. 20).  Thus, MI-4 can partially displace the classic DAT inhibitor 
cocaine at a concentration (10 µM) that lacks appreciable inhibition of dopamine uptake.  
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Figure 20.   MI-4 decreases the DUIP of cocaine. 
The inhibition of [3H]-dopamine uptake by cocaine in the absence (○) or presence 
(●) of 10 µM MI-4 at hDAT/N2A neuroblastoma cells (n = 3 experiments).  Reformatted 
with permission from ACS Chemical Neuroscience from Indarte et al., 2010. 
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MI-4 docking with the DAT comparative model suggests a series of binding 
modes.  The best-scoring (Affinity dG) binding mode of MI-4 indicates an array of 
interactions within the vestibular binding pocket (Fig. 21).  The benzylic hydroxyl group 
of MI-4 appears to establish H-bonds with Arg85 (TM 1) and Asp475 (TM 10).  This 
aromatic ring is also within reach of Tyr88, providing the potential for π-π aromatic 
stacking.  Asp384 in the fourth extracellular loop (ECL4a-4b) may also H-bond with a 
hydroxyl group of MI-4.  The charged amine from the benzylpiperidine is indicated to be 
able to form an H-bond with Thr472 (TM 10) in the current pose.   
 As suggested by the docking results, three mutated DAT proteins (R85D, 
R85D/D475R and D384A) were tested with MI-4 via [3H]-WIN 35,428 binding 
displacement assays.   MI-4 displayed a DAT binding affinity of 4.1 µM, while R85D 
mutation decreased affinity by 4-fold.  WT-like binding affinities were observed at the 
R85D/D475R and D384A DAT mutants.  In addition, other DAT mutants were tested 
with MI-4 via 3-point [3H]-WIN 35,428 binding displacement assays (three 
concentrations of MI-4 were applied: 0.5 µM, 2 µM and 10 µM) (Appendix 2, Fig 25).  
Some mutants displayed differently relative to the WT DAT, such as Y88A, T472A, and 
I468A.  WT-like binding affinity of MI-4 was observed at T472A (Appendix 5).  Further 
characterization is needed to determine MI-4 binding affinity at other DAT mutants. 
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Figure 21.   MI-4 docking in the DAT model  
Optimal positioning of MI-4 in the DAT vestibular pocket is depicted by the top-
ranked pose generated by MOE-Dock 2007.  For reference, the primary 
substrate/inhibitor pocket (below the vestibular pocket) is indicated by superpositions of 
docked dopamine (green) and the analogous position of leucine (orange, sticks) in LeuT.  
DAT vestibular pocket side chains (atom colored) within 5 Å of the docked MI-4 
molecule (yellow / atom colored) are shown.  Intermolecular H-bond interactions are 
indicated (pink dashed lines).  Pose generated by Dr. Martin Indarte.  Reprinted with 
permission from ACS Chemical Neuroscience from Indarte et al., 2010. 
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Table 8.  Affinity of MI-4 at N2A neuroblastoma cells transiently expressing DAT 
constructs. 
Ki values were derived from experiments incubating transiently transfected cells 
with MI-4 in the presence of [3H]-WIN35,428 at room temperature in KRH/AA buffer.  
Values represent the mean ± SEM from four independent experiments, each conducted in 
duplicate determinations. 
DAT Construct DAT binding affinity 
(Ki/µM) 
WT 4.1 ± 0.1 
R85D 16 ± 2.4* 
R85D/D475R 5.9 ± 1.4 
D384A 5.2 ± 1.0 
* P < 0.05 vs. WT DAT 
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2. Discussion 
In the present study, ten VS “hit” compounds were pharmacologically 
characterized via [3H]-WIN 35,428 displacement and [3H]-dopamine uptake inhibition 
assays.  MI-15, MI-17 and MI-20 displayed appreciable inhibition on WIN 35,428 
binding and dopamine uptake in initial screening assays (Fig. 17).  DAT affinity of these 
compounds was approximately 1 µM, and DUIP was approximately 3-fold lower than 
affinity (Fig. 18, Table 6), suggesting that the in vitro concentration needed to block 
dopamine uptake is approximately 3 times higher than the concentration needed to inhibit 
binding of WIN (a cocaine analog).  This finding implies that these novel compounds 
obtained by VS are capable of antagonizing a cocaine analog without appreciably 
disrupting the dopamine uptake function of the DAT.  In addition, to validate the model 
and the virtual screening method, 10 non-hit compounds were purchased and tested 
(Appendix 3).  Most compounds failed to show any inhibition on WIN 35,428 binding 
and dopamine uptake, only one compound displayed moderate inhibition on WIN 35,428 
binding and dopamine uptake.  These VS hits were also assessed with the SERT; only 
MI-17 displayed appreciable inhibition of RTI-55 binding and serotonin uptake (Fig. 19).  
In addition, MI-17 displayed an affinity at hSERT 4.5-fold higher than at hDAT.  The 
modified MI-17 analog remarkably increased SERT binding affinity (13-fold), and thus 
improved the drug selectivity (Table 7).   
Previously identified VS hit MI-4 interfered with cocaine binding at the DAT to 
the extent that cocaine DUIP was reduced 3-fold (Fig. 20).  Based on the suggestion of 
the docking results (Fig. 21), MI-4 affinity at mutated DAT proteins (R85D, 
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R85D/D475R and D384A) was tested (Table 8).  The change of the charge and side chain 
length might account for the observation of 4-fold loss of binding affinity at R85D DAT.  
WT-like affinity at the double mutant suggests that alterations by the single mutation 
were compensated for by the switch substitution, supporting the existence of the 
R85/D475 salt bridge.  D384 is indicated to establish H-bonding with a hydroxyl group 
of MI-4.  Therefore, alanine substitution was expected to change MI-4 binding by 
eliminating the possibility of H-bond formation.  However, WT-like affinity of MI-4 was 
observed at D384A, implying that the proposed H-bond might not form. 
The finding of MI-4, MI-15, MI-17 and MI-20 through VS experiments is 
promising, although it might be argued that micromolar affinity is at best sub-optimal.  
These compounds emerged from VS experiments utilizing a comparative protein model 
with very low sequence similarity to its template (21%).  The percentage of “hit” 
compounds is typically less than 1% of all compounds screened through VS or HTVS 
(Bailey and Brown 2001; Schneider and Bohm 2002).  Moreover, only low micromolar 
activities are typically obtained when homology models and not X-ray structures of 
targets are employed (Enyedy, Lee et al. 2001; Enyedy, Ling et al. 2001; Anand, Ziebuhr 
et al. 2003; Rajnarayanan, Dakshanamurthy et al. 2004; Dong, Sheng et al. 2010).  
Therefore, finding VS hits with nanomolar affinity was not expected.   
Successful identification of MI-4, MI-15, MI-17 and MI-20 reflects a structure-
based ligand discovery effort based on DAT inhibitor docking studies, supporting the 
hypothesis that the external vestibule (S2) substrate/inhibitor binding site of DAT protein 
can be used in in silico screening experiments to discover novel inhibitors or lead 
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compounds.  It was hoped that the VS experiment would yield an affordable commercial 
compound that could serve as a lead compound for development of a medication that 
modulated dopamine levels.  The successful modification of the MI-17 indicated that this 
is a proper strategy to discover lead compounds using the refined models for developing 
novel anti-addiction medications as well as therapeutics to combat depression, anxiety, 
Parkinson’s disease, narcolepsy, chronic pain, and other CNS-related maladies.  
Moreover, reliable ligand-transporter protein docking poses could help identify binding 
pocket residues to be tested via site-directed mutagenesis and subsequent pharmacology 
characterization.  The preliminary study of MI-4 partially confirmed the involvement of 
R85 and D475 suggested by the docking results (Table 8).  Thus, the results from 
mutagenesis and pharmacological study will further fine-tune the DAT model.   
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IV.  SUMMARY 
Our results may be of significance to ongoing efforts in the development of anti-
addiction medications.   In addressing whether the 3D DAT model could be useful for 
elucidating the ligand binding sites and aiding the rational design of novel therapeutics, 
the site-directed mutant pharmacology has confirmed some of the prediction from the 
DAT model, which is promising that the comparative DAT model is valid to some extent 
and could be further used for ligand docking and virtual screening.  Although some 
postulated mutants displayed wildtype-like profiles, it is still valuable information to 
refine the DAT model.  In addition, one methylphenidate analog bearing modest DAT 
affinity (363 ± 28 nM) was identified as potential non-tropane based photoaffinity probe 
via pharmacological assays.  This compound was further radiolabeled and successfully 
incorporated into the DAT protein, suggesting the use to identify protein-ligand direct 
contact at the amino acid level.  The photoaffinity labeling study could also help to 
validate and refine the DAT model.  With respect to the ability of the DAT model to 
discover novel DAT ligands, virtual screening experiments were done using the refined 
DAT model.  The top scored “hit” compounds were tested on bench, and 4 of them (MI-4, 
MI-15, MI-17 and MI-20) were identified as potential DAT ligands with low µM affinity.  
MI-4 also displayed affinities to SERT and NET.  MI-17 displayed 4.5-fold higher 
affinity at hSERT than at hDAT.  A modification on MI-17 dramatically increased SERT 
affinity without changing DAT affinity, indicating the successfully improved SERT/DAT 
selectivity. 
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The present study suggests the successful use of combined approaches including 
molecular modeling, mutant pharmacology and photoaffinity labeling to identify 
potential therapeutic compounds.  The identification of MI-4, MI-15, MI-17 and MI-20 
confirms the ability of the 3D model to screen and discover lead compounds for novel 
therapeutics to combat addiction and other neurological and psychiatric conditions such 
as Parkinson’s disease, depression, schizophrenia and ADHD.  
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Figure 22. Clomipramine inhibition of [3H]-WIN35,428 binding at N2A cells 
transiently expressing WT or D384A DAT. 
The inhibition of [3H]-WIN35,428 binding by clomipramine at N2A cells 
transiently transfected with WT (●) or D384A (▲) DAT (n = 3 experiments).   
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Figure 23. Affinity and DUIP of modafinil at hDAT/N2A neuroblastoma cells. 
Ki and IC50 values were derived from experiments incubating hDAT/N2A 
neuroblastoma cells with modafinil in the presence of [3H]-WIN35,428 (upper panel) and 
[3H]-dopamine (lower panel) at room temperature in KRH/AA buffer. Values represent 
the mean ± SEM from at least three independent experiments, each conducted in 
duplicate determinations. 
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Figure 24. Modafinil decreases the DUIP of cocaine. 
The inhibition of [3H]-dopamine uptake by cocaine in the absence (●) or presence 
(■) of 10 µM modafinil at hDAT/N2A neuroblastoma cells (n = 3 experiments). 
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Table 9.  Affinity of Modafinil at N2A neuroblastoma cells transiently expressing 
DAT constructs. 
Ki values were derived from experiments incubating transient transfected cells 
with modafinil in the presence of [3H]-WIN35,428 at room temperature in KRH/AA 
buffer.  Values represent the mean ± SEM from three independent experiments, each 
conducted in duplicate determinations (Only one experiment was done with T472A 
DAT).  
DAT Construct DAT binding affinity 
(Ki/µM) 
WT 1.2 ± 0.3 
R85D 5.8 ± 0.9* 
R85D/D475R 4.8 ± 1.7 
D384A 2.3 ± 0.3 
T472A                              2.0 
* P < 0.05 vs. WT DAT 
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Figure 25. Inhibition of [3H]-WIN35,428 specific binding by cocaine, modafinil 
and MI-4 at N2A cells expressing WT or mutant DAT proteins.  
DAT binding affinities were assessed via [3H]-WIN35,428 displacement when 
cocaine, modafinil and MI-4 (0.5 µM, 2 µM and 10 µM) were pre-incubated for cells 
transiently transfected with plasmid encoding WT and mutated DATs.  The data 
represent an average of at least 3 separate experiments. 
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Figure 26.   Initial DAT binding affinity and dopamine uptake inhibition screening 
for VS “non-hit” compound at N2A neuroblastoma cells stably expressing WT 
hDAT. 
 DAT binding affinities were assessed via [3H]-WIN35,428 displacement when 
BS-1 to BS-9 (10 µM) were co-incubated (upper panel).  [3H]-dopamine uptake 
inhibition was assessed by incubation with BS-1 to BS-9 (10 µM) (lower panel). The data 
represent an average of at least 3 separate experiments. 
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Figure 27. Affinity of WIN 35,428 at N2A neuroblastoma cells transiently 
expressing HA tagged DAT. 
Ki value was derived from experiments incubating transient transfected (HA-
tagged DAT) cells with nonradioactive WIN in the presence of [3H]-WIN35,428 at room 
temperature in KRH/AA buffer. Value represents the mean ± SEM from three 
independent experiments, each conducted in duplicate determinations. 
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Figure 28. Affinity of MI-4 at N2A neuroblastoma cells transiently expressing 
T472 DAT. 
Ki value was derived from experiments incubating transient transfected cells with 
MI-4 in the presence of [3H]-WIN35,428 at room temperature in KRH/AA buffer. Value 
represents the mean ± SEM from three independent experiments, each conducted in 
duplicate determinations. 
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APPENDIX 6 
Melatonin is a neurohormone mainly secreted by the pineal gland that follows a 
circadian rhythm with its highest concentrations at night.  The cloning of genes encoding 
melatonin receptors has revealed three melatonin receptor subtypes (MT1, MT2 and MT3).  
The MT1 melatonin receptor belongs to the G-protein coupled receptor (GPCR) 
superfamily.  It is involved in modulating several physiological processes that triggered 
by melatonin, such as circadian rhythm and constricting cardiac blood vessels.  The 
ability of melatonin to bind to, activate, and modulate MT1 receptors depends on the 
interaction of melatonin with specific amino acids and/or domains.  Several highly 
conserved structural “motifs” which are postulated to govern receptor function have been 
uncovered by comparing GPCR amino acid sequences; MT1 receptor is unusual in its 
divergence at these motifs.  In order to test the hypothesis that one of these motifs, the 
GPCR “aromatic cluster” motif in TM6 and its “toggle switch” position 6.52 are involved 
in MT1 receptor ligand binding and activation, selective substitutions were made to the 
amino acid comprising this motif and their effects on ligand binding were observed. 
Aromatic cluster sequences 
Most GPCRs:           “F6.44XXXW6.48XXXF6.52” 
Melatonin receptor: “F6.44XXXW6.48XXXN6.52” 
Transiently-transfected COS 7 cells and stable CHO cell lines expressing wild 
type and mutant MT1 receptors were assayed for ligand binding.  Asparagine (N) side 
chain at position 6.52 is proposed to control the contribution of the aromatic cluster to 
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receptor activation.  Alanine (A) substitution of this amino functional group is predicted 
to disrupt hydrogen-bonding potential while preserving helical structure.  Phenylalanine 
(F) substitution will add aromaticity and eliminate the hydrogen-bonding potential.  
Histidine (H) substitution will keep the hydrogen-bonding potential while adding 
aromaticity.  All these alterations are proposed to disrupt the molecular interactions 
within the receptor important for ligand recognition.  The 1-point [125I]-iodomelatonin 
binding assay (Fig 29) showed that only N6.52A displayed detectable binding, while 
N6.52F and N6.52H failed to show any specific binding, suggesting that the increased 
steric hindrance by adding aromatic ring to this position might be the reason for the loss 
of ligand binding.  N6.52A MT1 receptor displayed WT-like binding affinity for 
iodomelatonin (Fig 30, Table 10).  Given the observation that the number of drug-
accessible N6.52A MT1 molecules measured by maximal [125I]-iodomelatonin binding 
(Bmax) was 3-fold lower than WT (Table 10), the loss of net binding (Fig 29, 30) can 
largely be accounted for by the loss of MT1 expression.  Competitive binding results 
showed that antagonist luzindole Ki values higher for the mutant receptor (Fig 31, Table 
11), implying that N6.52 amino acid residue might be more important for antagonist 
binding than that of agonist.  Binding assays involving structurally different ligands and 
receptor mutagenesis will further evaluate the role of the aromatic motif in the function of 
the MT1 receptor.  Understanding these motif amino acids should be helpful in providing 
a template for therapeutic drug design. 
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Figure 29. Determination of [125I]-iodomelatonin specific binding by COS 7 cells 
expressing WT or N6.52 mutant MT1 receptor proteins. 
The extent of specific [125I]-iodomelatonin binding as a percentage of WT MT1 
was assessed for cells transiently transfected with plasmids encoding N6.52A, N6.52F, 
N6.52H MT1, or the plasmid vector lacking MT1 sequence (pIRESneo).  The data 
represent an average of 3 separate experiments. 
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Figure 30. Specific [125I]-iodomelatonin binding at CHO cells stably expressing 
WT or N6.52A MT1 receptor proteins. 
Hot [125I]-iodomelatonin saturation binding was assessed for CHO cells stably 
transfected with plasmids encoding WT or N6.52A MT1 receptor (n = 3 experiments).   
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Table 10.  Affinity of [125I]-iodomelatonin at CHO cells stably expressing MT1 
constructs. 
Kd and Bmax values were derived from experiments incubating stably transfected 
CHO cells with [125I]-iodomelatonin.  Values represent the mean ± SEM from three 
independent experiments, each conducted in duplicate determinations.  
 MT1 Construct Kd (pM) Bmax (fmol/mg) 
WT  92 ± 4 1074 ± 165 
N6.52A  120 ± 9 312 ± 75* 
* P < 0.05 vs. WT MT1 
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Figure 31. Specific [125I]-iodomelatonin binding at CHO cells stably expressing 
WT or N6.52A MT1 receptor proteins. 
Hot [125I]-iodomelatonin saturation binding was assessed for CHO cells stably transfected 
with plasmids encoding WT or N6.52A MT1 receptor (n = 3 experiments). 
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Table 11.  Affinity of melatonin and luzindole at CHO cells stably expressing MT1 
constructs.  
Ki values were derived from experiments incubating stably transfected CHO cells 
with nonradioactive melatonin or luzindole in the presence of [125I]-iodomelatonin.  
Values represent the mean ± SEM from three independent experiments, each conducted 
in duplicate determinations.  
 MT1 Construct Melatonin 
Ki (pM) 
Luzindole 
Ki (pM) 
WT  24 ± 10 6.2 ± 3.8 
N6.52A  29 ± 9 30 ± 22* 
* P < 0.05 vs. WT MT1 
 
